



## รายงานวิจัยฉบับสมบูรณ์

โครงการ: การค้นหา cytotoxic T lymphocyte epitopes ของ latent membrane protein  
1 จาก Epstein-Barr virus ที่พบในมะเร็งหลังโพรงจมูกในประเทศไทย

โดย

พญ. ดร. ณีฎฐิยา พิมทะโนทัย

ภาควิชาจุลชีววิทยา คณะแพทยศาสตร์  
จุฬาลงกรณ์มหาวิทยาลัย

กรกฎาคม พ.ศ. 2546

รายงานวิจัยฉบับสมบูรณ์

โครงการ: การค้นหา cytotoxic T lymphocyte epitopes ของ latent membrane protein  
1 จาก Epstein-Barr virus ที่พบในมะเร็งหลังโพรงจมูกในประเทศไทย

พญ. ดร. ณัฏฐิยา พิมพ์โนทัย

ภาควิชาจุลชีววิทยา คณะแพทยศาสตร์  
จุฬาลงกรณ์มหาวิทยาลัย

สนับสนุนโดยสำนักงานกองทุนสนับสนุนการวิจัย

(ความเห็นในรายงานนี้เป็นของผู้วิจัย สกว. ไม่จำเป็นต้องเห็นด้วยเสมอไป)

## **ACKNOWLEDGEMENT**

The authors are deeply indebted to the staff of the Department of Otolaryngology and the Radiotherapy section, Department of Radiology, Chulalongkorn University, for the recruitment of patients and collection of materials. This work was supported by the Thailand Research Fund, the Molecular Biology Research Fund, Faculty of Medicine, Chulalongkorn university, and the Asahi Glass Foundation, Oversea Research Grant 2001.

## บทคัดย่อ

รหัสโครงการ : PDF/25/2544

ชื่อโครงการวิจัย: การค้นหา cytotoxic T lymphocyte ของ latent membrane protein 1 จากไวรัสเอปสไตน์บาร์ที่พบในมะเร็งหลังโพรงจมูกในประเทศไทย

ชื่อผู้วิจัย: ผศ. พญ. ดร. ญัตติยา หิรัญกาญจน์ (พิมพ์โนทัย) หน่วยภูมิคุ้มกันวิทยา ภาควิชาจุลชีววิทยา คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย

E-mail Address: [fmednpt@md.chula.ac.th](mailto:fmednpt@md.chula.ac.th)

ระยะเวลาดำเนินงาน: กรกฎาคม 2544 ถึง มิถุนายน 2546

การกระตุ้นภูมิคุ้มกันเชิงเซลล์ชนิด cytotoxic T lymphocyte ที่จำเพาะต่อโปรตีนของไวรัสเอปสไตน์บาร์ที่สัมพันธ์กับมะเร็งหลังโพรงจมูกเป็นแนวทางหนึ่งในการพัฒนาแนวทางการรักษาต่อโรคมะเร็งหลังโพรงจมูก การศึกษานี้เป็นขั้นตอนหนึ่งที่จะนำไปสู่การพัฒนาการรักษานั้น เริ่มด้วยการศึกษารูปแบบของ HLA class I ของผู้ป่วยโรคมะเร็งหลังโพรงจมูกในประเทศไทย เนื่องจากข้อมูลเกี่ยวกับรูปแบบของ HLA class I ชนิดที่พบได้บ่อยมีประโยชน์ในขบวนการค้นหาส่วนของเปปไทด์ที่สามารถกระตุ้น cytotoxic T lymphocyte ได้ ชนิดของ HLA ที่พบได้บ่อยมากกว่า 10% ในประเทศไทย ได้แก่ A2 (58%), A11 (43%), A19 (A33) (32%), A9 (A24) (26%), B46 (30-46%), B40 (B60) (19-24%), B58 (12-24%), B12 (B44) (9-11%), and B75 (11%) นอกจากนั้นการศึกษานี้ยังรวมถึงการหาลำดับเบสของ LMP1 โดยใช้ตัวอย่างชิ้นเนื้อของมะเร็งหลังโพรงจมูกจากประเทศไทย โดยเน้นที่บริเวณที่เป็น CTL epitopes ที่มีผู้ศึกษาไว้แล้วเพื่อระดับของความหลากหลายในบริเวณนั้น โดยสรุป CTL epitopes 2 ชนิดที่จำเพาะกับ HLA A2 (ALLVLYSFA and LLLIALWNL) และ อีก 2 ชนิดที่จำเพาะกับ HLA B31/33 และ B61 (SDSNSNEGR and NEGRHLLV) จากไวรัสเอปสไตน์บาร์ในประเทศไทยมีลำดับเบสที่มีความเหมือนกันกับข้อมูลเดิมจากประชากรอื่นๆค่อนข้างสูง อย่างไรก็ตามผลของไวรัสเอปสไตน์บาร์จากชิ้นเนื้อมะเร็งหลังโพรงจมูกจากประเทศไทยแสดงถึงการเปลี่ยนแปลงที่ทำให้เกิดการเปลี่ยนชนิดของกรดอะมิโนในบางตำแหน่งด้วย ส่วน CTL epitope อีก 1 ชนิดที่จำเพาะกับ HLA A2 (YLLEMLWRL) นั้นมีลำดับเบสคล้ายคลึงกับข้อมูลจากประเทศจีน (YFLEILWRL) การศึกษาสุดท้ายคือการค้นหาส่วนของเปปไทด์ที่สามารถกระตุ้น cytotoxic T lymphocyte จากโปรตีนของไวรัสเอปสไตน์บาร์ที่สัมพันธ์กับมะเร็งหลังโพรงจมูกที่จำเพาะกับ HLA class I ชนิดที่พบได้บ่อยในประเทศไทยตรวจโดยใช้ชุดของ overlapping peptide ในตัวอย่างคนไทย 20 ราย ผลการตรวจพบว่ามีเพียง 2 ใน 20 รายที่แสดงผลบวกต่อเปปไทด์ขนาดยาว 1 ชนิด (SNSNEGRHLLVSGAGDD) อย่างไรก็ตามผลนี้ต้องการการศึกษาเพิ่มเติมเพื่อค้นหาเปปไทด์ขนาดสั้นภายในนั้นรวมถึงการบ่งชี้ชนิดของ HLA ที่จำเพาะต่อเปปไทด์นี้ต่อไป

คำหลัก: NPC, EBV, CTL epitope, LMP1, HLA

## ABSTRACT

**Project Code:** PDF/25/2544

**Project Title:** Mapping of cytotoxic T lymphocyte epitopes within latent membrane protein 1 from nasopharyngeal carcinoma-associated Epstein-barr virus in Thai population

**Investigators:** Nattiya Hirankarn (Pimtanothai) Immunology Unit, Department of Microbiology, Faculty of Medicine, Chulalongkorn University

**E-mail Address:** fmednpt@md.chula.ac.th

**Project Period:** July 2001-June 2003

To develop a therapeutic tool for the treatment of NPC by the delivery of a curative EBV-specific immune response to NPC patients, one approach is to stimulate the CTL against EBV antigen present in the tumor cells. As a first step toward that goal, this study characterized HLA class I distribution from Thai NPC patients since the HLA information particularly the one common in the endemic area is very useful for the characterization process of CTL epitopes. The common HLA antigens with antigen frequencies (AgF) of more than 10% in Thai NPC were A2 (58%), A11 (43%), A19 (A33) (32%), A9 (A24) (26%), B46 (30-46%), B40 (B60) (19-24%), B58 (12-24%), B12 (B44) (9-11%), and B75 (11%). In addition, this study characterized LMP1 sequence from Thai NPC biopsy, particular focusing on the region containing previously identified LMP1 epitopes to assess their degree of variability. In summary, the 2 HLA A2-restricted (ALLVLYSFA and LLLIALWNL) and HLA B31/33 & B61-restricted (SDSNSNEGR and NEGRHHLLV) epitopes were highly conserved in virus isolates from Thai NPC biopsy compared to available data. However, data from Thai NPC isolates revealed unique sequence which resulted in amino acid substitution. As for the more diverse HLA A2-restricted epitope, YLLEMLWRL, Thai isolates had similar sequences as other isolates from Chinese (YFLEILWRL). Lastly, the CTL epitopes within NPC-associated LMP1 antigen restricted through common HLA class I alleles prevalent in Thai population were mapped by screening overlapping peptides in 20 donors. Only 2 out of 20 donors gave positive responses to a long peptide (SNSNEGRHHLLVSGAGDD containing a potential novel epitope). However, the minimal epitope and HLA-restriction of the epitope still need further characterization.

**Keywords** NPC, EBV, CTL epitope, LMP1, HLA

## EXECUTIVE SUMMARY

NPC is one of the most common forms of cancer in some regions of China and South-East Asia and occurs less commonly in North Africa. Although patients with early stage of the disease are highly curable by radiotherapy, about 10% of the patients might not respond to the treatment. In addition, patients with advanced lesions are poorly controlled by radiation and recurrences are usually occurred within 5 years leading to only 10-40% five year survival rate. Since NPC is strongly associated with EBV infection, the stimulation of the patient's immune responses against the viral antigens might provide a useful tool of rejecting these virus associated tumor cells. To develop a therapeutic tool for the treatment of NPC by the delivery of a curative EBV-specific immune response to NPC patients, one approach is to stimulate the CTL against EBV antigen present in the tumor cells. As a first step toward that goal, this study characterized HLA class I distribution from Thai NPC patients compared to normal healthy control since the HLA information particularly the one common in the endemic area is very useful for the characterization process of CTL epitopes. The common HLA antigens with antigen frequencies (AgF) of more than 10% in Thai NPC were A2 (58%), A11 (43%), A19 (A33) (32%), A9 (A24) (26%), B46 (30-46%), B40 (B60) (19-24%), B58 (12-24%), B12 (B44) (9-11%), and B75 (11%). In addition, this study characterized LMP1 sequence from Thai NPC biopsy, particular focused on the region containing previously identified LMP1 epitopes. The HLA A2-restricted (ALLVLYSFA and LLLIALWNL) and HLA B31/33 & B61-restricted (SDSNSNEGR and NEGRHHLLV) epitopes were highly conserved in virus isolates from Thai NPC biopsy compared to available data. However, data from Thai NPC isolates revealed unique sequence which resulted in amino acid substitution. As for the HLA A2-restricted epitope, YLLEMLWRL, Thai isolates had similar sequences as other isolates from Chinese (YFLEILWRL). Lastly, the CTL epitopes within NPC-associated LMP1 antigen restricted through common HLA class I alleles prevalent in Thai population were mapped by screening overlapping peptides in 20 donors. Only 2 out of 20 gave positive responses to a 18-mer peptide (SNSNEGRHHLLVSGAGD). However, the minimal epitope and HLA-restriction of the epitope still need further characterization. Since this protein is poorly immunogenic, to target EBV-positive NPC tumor, such small response against LMP1 should be amplified. Therefore, more donors should be included to obtain more putative CTL epitopes of LMP1.

## **LIST OF SYMBOLS**

|               |                                             |
|---------------|---------------------------------------------|
| NPC           | NASOPHARYNGEAL CARCINOMA                    |
| EBV           | EPSTEIN BARR VIRUS                          |
| LMP           | LATENT MEMBRANE PROTEIN                     |
| EBNA          | EPSTEIN BARR VIRUS NUCLEAR ANTIGEN          |
| HLA           | HUMAN LEUKOCYTE ANTIGEN                     |
| CTL           | CYTOTOXIC T LYMPHOCYTE                      |
| IFN- $\gamma$ | INTERFERON GAMMA                            |
| PTLD          | POST TRANSPLANT LYMPHOPROLIFERATIVE DISEASE |
| PBMC          | PERIPHERAL BLOOD MONONUCLEAR CELL           |
| PCR           | POLEMERASE CHAIN REACTION                   |

## INTRODUCTION

NPC is one of the most common forms of cancer in some regions of China and South-East Asia and occurs less commonly in North Africa. Although patients with early stage of the disease are highly curable by radiotherapy, about 10% of the patients might not respond to the treatment. In addition, patients with advanced lesions are poorly controlled by radiation and recurrences are usually occurred within 5 years leading to only 10-40% five year survival rate. Since NPC is strongly associated with EBV infection, the stimulation of the patient's immune responses against the viral antigens might provide a useful tool of rejecting these virus associated tumor cells. The link between EBV and the geographically constrained NPC is not entirely clear but is believed to be influenced by dietary and genetic factors. It is now well established that these tumor cells, like many other EBV-associated malignancies, express a limited number of EBV antigens thus restricting the potential targets for immune recognition (reviewed in Khanna and Burrows, 2000). Many laboratories were studying the immune mechanisms responsible for protecting healthy individuals from a recrudescence of infection with EBV. They have shown that the main immunological arm responsible for this protection involves cytotoxic T lymphocytes (CTL) although these T cells fail to control the outgrowth of some EBV-associated malignancies (reviewed in Khanna *et. al.* 1995; reviewed in Khanna *et. al.* 1999a; reviewed in Rickinson & Moss 1997).

In the case of NPC, the precise mechanism of immune escape is unclear. Earlier studies have suggested that most NPC patients retain detectable EBV-specific T cell surveillance, indicating that CTL dysfunction is an unlikely cause of the outgrowth of these tumors *in vivo* (Moss *et. al* 1983). Based on studies in healthy individuals, it is likely that this response is strongly focussed through epitopes within the EBV nuclear antigens (EBNA) 2-6 proteins with minimal HLA class I-restricted reactivity against latent membrane proteins (LMP1 & LMP2) and none within EBNA1 (Levitskaya *et al*, 1995). Since NPC tumor cells express only EBNA1 and LMP1 & 2, the existing EBV-specific CTL repertoire in NPC patients may have a limited capacity to control this tumor *in vivo*. The lack of class I-restricted processing of EBNA1 has directed an increasing interest in designing strategies to enhance the response to LMP epitopes to control NPC. Before such strategies can be designed it is important to precisely map the CTL responses to

EBV antigens expressed in NPC. Previously attempts to map such responses have been constrained by the ability to expand virus-specific CTLs *in vitro* to numbers which allow functional analysis in cytotoxicity assays. A major advancement in screening protocols has come with development of a rapid single cell assay which is based on the peptide induced secretion of interferon  $\gamma$  (IFN- $\gamma$ ) by T cells (also referred to as ELISPOT assay). This assay allows a rapid means of profiling epitope-specific CTL responses without long-term *in vitro* manipulation.

Currently, most of the defined CTL epitopes from LMP were characterized from the Caucasian healthy donors (reviewed in Khanna et al., 1999a, donors (reviewed in Khanna and Burrow, 2000). Since it has recently been shown that the EBV strains in China and Southeast Asia NPC patients possess a unique LMP sequences (Hu et al., 1991; Miller et al., 1994; Busson et al., 1995; Walling et al., 1999; Khanna et al., 1997a); therefore, new epitopes identified from EBV strain found in these population is also required. Moreover, it is necessary to identify additional epitopes restricted to common HLA type in Southeast Asia population.

The overall long-term aim of this project is to develop a rational basis for the delivery of a curative EBV-specific immune response to NPC patients. One approach is to stimulate the CTL against EBV antigen present in the tumor cells by immunizing protocol. It is anticipated that these T cells subsequent to the completion of this project will be used as a therapeutic tool for the treatment of NPC by analogy to that used for other EBV-associated cancers (reviewed in Rooney et al., 1998a; reviewed in Heslop et al., 1997). As a first step toward our goal, this study proposes to 1) characterize HLA class I distribution from Thai NPC patients compared to normal healthy control, 2) characterize LMP1 sequence from Thai NPC patients compared to available data, and 3) map the CTL epitopes within NPC-associated LMP1 antigen restricted through common HLA class I alleles prevalent in Thai population.

## **PROCEDURE**

### **Experimental design**

This study proposed to characterize LMP1 sequence from EBV strain commonly found in Thai NPC patients and compared with the available data to synthesize a set of overlapping peptide to use for the epitope mapping in Thai population. The donor will be selected from healthy carriers who carry common HLA class I alleles prevalent in Thai population as shown in table 6. Overlapping peptides will be prepared and tested. In brief, the LMP1 protein contains 386 amino acids (Kieff, 1996), the total of forty-five overlapping peptides were synthesized and tested in this study.

### **Methods**

#### **Study Population for HLA study.**

The study population consists of (1) newly diagnosed NPC patient, (2) long term survival patient, and (3) EBV-positive healthy donors in Thailand. Specifically, we recruited the patients who attend King Memorial Chulalongkorn Hospital that have been diagnosed as undifferentiated NPC by accepted histopathological criteria. The long term survival group is the NPC patients who had been previously treated with radiotherapy or combined radio-chemotherapy and were free of clinical disease at the time of the study for more than 1 year. The healthy carrier individuals of Thai origin were recruited from donors at the Thai Red Cross Society. After obtaining an informed consent, peripheral blood samples were taken from healthy EBV-positive donors and NPC patients. Blood were fractionated on Ficoll density gradients, and PBMC were collected to be used in HLA serological typing and the ELISPOT assay. In addition, DNA were prepared from peripheral blood samples and from serum using Qiamp DNA blood mini kit (Qiagen, Basel Switzerland) according to the "blood and body fluid protocol".

#### **Study population for CTL mapping.**

After obtaining informed consent, healthy virus carrier with required-HLA class I allele, and is homozygous on that locus if possible, were recruited as donor in this study. Approximately 20 donors were included in the CTL screening process.

### **Determination of HLA Alleles.**

HLA-A and HLA-B alleles were determined using standard microcytotoxicity test, which is a methodology routinely performed in Immunology unit, Chulalongkorn University. Briefly, lymphocyte separation and HLA typing were performed from freshly drawn blood by standard microlymphocytotoxicity assay. The panel of 70 antisera were used to defined the 17 HLA-A antigens and 30 HLA-B antigens. The antigen frequencies were determined by direct counting.

Certain HLA alleles such as HLA-A2 subtype were determined using the DNA-based Sequence Specific Primer (SSP) typing procedure (Krausa et al., 1995). In addition, the high resolution typing of HLA-B locus were done by direct sequencing of the PCR products using primers BIN1-TA, BIN1-CG and BIN3, which amplified exons 2 and 3 and intron 2 as previously described (Pimtanothai et al., 2000).

### **LMP Sequencing.**

LMP1 gene were amplified from genomic DNA prepared from NPC tumor biopsy using LMP1-specific primers. Then the PCR were purified and subjected to direct sequencing using automated sequencer (310 Genetic Analyzer). Samples randomly selected from a pool of ~ 200 samples of NPC tumor DNA have been previously prepared and will be kindly given to us by Dr. Mutirangura.

### **DNA sequencing.**


For direct cycle sequencing, 40 µl of the PCR products were purified by the QIAquick PCR Purification Kit (QIAGEN Inc.) to obtain clean double-stranded DNA amplicates. Cycle sequencing was performed on an ABI Prism 310 Genetic Analyzer using a cycle sequencing chemistry with base-specific fluorescence – labeled dideoxynucleotide termination reagents, BigDye Terminator Ready Reaction Mix (Applied Biosystems) was used for sequencing. Thus, each sequencing reaction mixture of 10 µl final volume contained 1 µl of 5 pmol primer, 3 µl of template and 3 µl of the BigDye Terminator Ready Reaction Mix. Each sample mixture was then subjected to a cycle sequencing reaction in a Perkin Elmer/GeneAmp PCR system 2400 or Applied Biosystems/GeneAmp PCR system 9000. The condition of cycle sequencing reaction consisting of denaturation at 96<sup>o</sup> c for 30 seconds, annealing at 55<sup>o</sup> c for 10 seconds and extension at 60<sup>o</sup> c for 4 minutes were carried out. Then each sequencing reaction product was pooled into 2 µl of 3 M sodium acetate (NaOAc), pH4.6/50 µl of 95% ethanol (EtOH) mixture in 1.5 microcentrifuge tubes, incubated at room temperature for

15 minutes to precipitate the extension products and centrifuged at 13,000 rpm for 20 minutes. The products were washed with 70% ethanol (EtOH) and centrifuged for 5 minutes at 13,000 rpm. The DNA pellet was then dried by place the tubes with the lids open in a heat block or thermal cycler at 90<sup>o</sup> c for 1 minute. Finally, the samples were resuspended in 15 µl of TSR (template suppression reagent), heat the samples at 95<sup>o</sup> c for 2 minutes and then chill on ice. The samples were loaded into an ABI Prism 310 Genetic Analyzer. Data collection was performed using the software package provided with the ABI 310 a sequencing system.


### **Overlapping peptides.**

In the screening process, segments of 20 amino acids, overlapping by 10 amino acids and spanning the entire molecule based on the sequencing data were synthesized by Chiron Technologies using the solid phase method. In addition, segments of 9 amino acids, overlapping by 1 amino acid, spanning the region of the 18-20-mers that gives positive result in the ELISPOT assay will be synthesized by the same method. One 18-20-mers peptide was composed of twelve 9-mers peptides. The rational for this design is because the usual length of CTL epitope is ~9-10 aa long. Peptides were dissolved in DMSO, and diluted in serum-free RPMI 1640 medium for use in the ELISPOT assay.

## Amino acids in LMP1



## Selected 18-20-mer peptide



**Figure 1. a diagram shows an example of the overlapping segments**

## ELISPOT assay for single cell IFN- $\gamma$ release.

Nitrocellulose membrane-base 96 well plates were precoated with anti-IFN- $\gamma$  monoclonal antibody. PBMC (250,000 cells/well) were added in the presence of each peptide at a predetermined optimal concentration ( $\sim 5$ - $10 \mu\text{g/ml}$ ) in triplicate and incubated overnight. The cells were discarded the following day and incubated with biotinylated anti-IFN- $\gamma$  monoclonal antibody, followed by streptavidin-conjugated alkaline phosphatase. Individual IFN- $\gamma$  producing cells were detected as dark spots after adding the substrate and can be counted using dissection microscope.

## RESULTS

### The distribution of HLA-A and HLA-B in NPC patients compared to normal control

The study population included 53 unrelated Thai patients with histologically confirmed NPC diagnosed at King Chulalongkorn Memorial Hospital in Bangkok. There were 34 men and 20 women, with a median age of 48 years (range, 16-81). All of these patients were positive for the EBNA1 gene in tumor cells as detected by PCR as reported previously (Mutirangura et al., 1997 and 1998). Seventy healthy unrelated Thai individuals served as ethnically and geographically matched controls.

The distribution of HLA-A and -B antigens between the two groups is shown in Table 1 and 2. A total of 10 HLA-A antigens and 23 HLA-B antigens were observed in the Thai control group. The common HLA antigens with antigen frequencies (AgF) of more than 20% in Thai controls were A2 (38.5%), A9 (A24) (42.8%), A11 (48.6%), A19 (A33) (34.3%), B12 (B44) (20%), B13 (22.8%), and B40 (B60) (22.8%). Ten HLA-A antigens and 21 HLA-B antigens were detected in NPC patients with the same 4 common HLA-A antigens observed at high frequencies (26.4-58.5%). However, the common HLA-B antigens in NPC patients were different from the control group. B17 (B58) and B46 antigens were present in the patient group with the high AgF of 24.5% and 30.2%, respectively.

The HLA-B antigens are highly polymorphic with more than 100 alleles described. In addition, many HLA-B alleles have been previously described as an important associated factor with NPC. Therefore, we have also performed a high resolution typing of HLA-B by direct sequencing method in a subset of sample (54 NPC patients compared to 49 controls). The distribution of HLA-B alleles between the two groups is shown in Table 3. A total of thirty-four HLA-B alleles was observed in the Thai control group including one new allele (B\*3804) (Steiner et al., 2001). The five most common alleles in Thai controls were B\*44032 (28.5%), B\*4601 (16.3%), B\*1502 (16.3%), B\*4001 (14.2%), and B\*5801 (12.2%). Twenty-nine alleles were detected in NPC patients with the same five common alleles observed at high frequencies (11.1-46.3%). In addition, the allele frequencies of B\*38021 (11.1%) and B\*51012 (12.9%) were high in the patient group compared to controls.

The summarized of HLA-A and HLA-B alleles commonly present in Thai NPC patients which are the main target population was shown in Table 4.

### **Association between certain HLA class I alleles with NPC**

When the frequency of HLA-A and B antigens in NPC patients and normal individuals was compared, significant associations between NPC and 2 HLA antigens were observed, as summarized in Table 5. Specifically, the frequencies of A2 and B46, were significantly increased in NPC patients (58 and 30% vs. 38 and 14%,  $p = 0.02$  and  $p = 0.03$ , respectively).

When the frequency of high-resolution HLA-B alleles in NPC patients and normal individuals was compared, significant associations between NPC and three HLA-B alleles were observed, as summarized in Table 6. In conclusion, this study reported a protective B\*44032 allele and two susceptible, B\*4601 and B\*51012 alleles, for NPC in Thai population.

### **Sequence analysis of HLA class I-restricted LMP1 CTL epitopes in EBV isolates from Thai NPC**

In the previous studies, target epitopes in LMP1 were identified using CTLs reactivated with the reference type1 EBV strain, B95.8. However, if such epitopes are to form the basis of an effective CTL therapy for EBV-associated malignancies, we must first determine the extent to which these epitope sequences are conserved among other EBV strains from different world populations. Therefore, a panel of Thai NPC biopsies were sequenced across the DNA regions encoding for the LMP1 epitopes and compared with previous data of EBV isolates from other reports. Specifically, CAO strain is the EBV isolate derived from NPC biopsy from Chinese patient (Figure 6). C15 strain is the EBV isolate derived from a white Mediterranean NPC patient. Raji strain is the EBV isolate derived from an African Burkitt's lymphoma cell line.

A detailed summary of the sequence analysis of four previously identified LMP1 epitopes (ALLVLYSFA, YLLEMLWRL, LLLIALWNL, SDSNSNEGR and NEGRHLLV) is presented in Table 7. The HLA A2-restricted (ALLVLYSFA and LLLIALWNL) and HLA

B31/33 & B61-restricted (SDSNSNEGR and NEGRHLLV) epitopes were highly conserved in virus isolates from various sources (Table 7). Only a small number of virus isolates showed minor variation within the epitope sequences. However, data from Thai NPC isolates revealed unique sequence which resulted in amino acid substitution. For example, the substitution of serine instead of isoleucine at position 4 in the LLL[S-> I] ALWNL epitope. The substitution of threonine instead of serine at position 1 in the [T-> S]DSNSNEGR epitope. And the substitution of arginine instead of histidine at position 6 in the NEGRH[R->H]LLV.

Sequence analysis of the HLA A2-restricted epitope, YLLEMLWRL in EBV

In Thai isolates, leucine at position 2 and methionine at position 5 were substituted for phenylalanine and isoleucine, respectively (YFLEILWRL). No wild-type sequence was detected in any of the isolates from South-East Asia. A unique nucleotide substitution of A instead of G at position 12 was also observed although resulted in a silent mutation.

#### **The screening for T cell responses using a set of overlapping peptide from LMP1**

CTL epitopes were identified by their ability to stimulate T cell response in the ELISPOT assay. First, each 20-mer peptide was tested with lymphocytes in a single well.

Twenty-one healthy donors who carry at least one common HLA allele described in NPC patient as shown in table 4 were recruited for this study. List of donor and their HLA types was shown in table 8.

Out of 21 donors, only 2 donors gave positive result to one overlapping peptide designated peptide#28 (SNSNEGRHLLVSGAGDD). Specifically gamma-interferon ELISPOT reaction from donor AT (HLA-A11, A31; B13, B51) gave 60 spot forming cells (SFC) / PBMC  $10^6$  cells and reaction from donor SP (HLA-A11, A24; B18, B27) gave 20 SFC/million cells (Table 9). None of the other overlapping peptides can significantly stimulate gamma-interferon production from all the 21 donors. These positive result with peptide#28 was confirmed by repeating the ELISPOT assay which gave similar results (data not shown).

Peptide#28 contains two previously characterized CTL epitopes, B31/33 and B61-restricted SDSNSNEGR and NEGRHHLLV, respectively. We further tested PBMC from the 2 donors with these 2 well-defined epitopes. However, no spot were detected from either donor against SDSNSNEGR or NEGRHHLLV (table 9) suggesting that other minimal epitopes might be important.

Due to the limited budget, we apply bioinformatic technology to further predict a minimal epitope from peptide#28 instead of the original approach of making 9-mer peptides spanning the entire length of the 18-mer peptide. Using program "Binding Motif Scanner" from the HLA molecular Immunology database (<http://hiv.basic.nwu.edu/HLA/Reports/DoMotifList.cfm>), we search the entire amino acid sequence of LMP1 for putative CTL epitopes restricted to HLA alleles of the 2 donors (A11, A24, A31, B27, B51). However there are no binding motif of HLA-B13, B18 available in the database. Summary of the predicted result was shown in table 10. A number of putative epitopes (35 distinct sequences) were predicted. However, only 2 sequences were lying within peptide#28, indicated as bold letter in table 10 as B27-restricted GRHHLLVSG and B51-restricted EGRHHLLV.

**Table 1. HLA-A frequencies in patients with NPC and healthy controls from Thailand**

| HLA antigen | NPC Patients<br>(N =53) |       | Controls<br>(N = 70) |       |
|-------------|-------------------------|-------|----------------------|-------|
|             | n                       | AgF % | n                    | AgF % |
| A1          | 3                       | 5.6   | 3                    | 4.2   |
| A2          | 31                      | 58.5  | 27                   | 38.5  |
| A3          | 2                       | 3.7   | 3                    | 4.2   |
| A9 (A23)    | 0                       | 0     | 0                    | 0     |
| A9 (A24)    | 14                      | 26.4  | 30                   | 42.8  |
| A10 (A25)   | 0                       | 0     | 0                    | 0     |
| A10 (A26)   | 4                       | 7.5   | 1                    | 1.4   |
| A10 (34)    | 0                       | 0     | 0                    | 0     |
| A11         | 23                      | 43.3  | 34                   | 48.6  |
| A19 (A29)   | 0                       | 0     | 1                    | 1.4   |
| A19 (A30)   | 1                       | 1.8   | 4                    | 5.7   |
| A19 (A31)   | 0                       | 0     | 2                    | 2.8   |
| A19 (A32)   | 0                       | 0     | 0                    | 0     |
| A19 (A33)   | 17                      | 32    | 24                   | 34.3  |
| A19 (A74)   | 2                       | 3.7   | 0                    | 0     |
| A28         | 1                       | 1.8   | 0                    | 0     |
| A36         | 0                       | 0     | 0                    | 0     |

N = the total number of individuals studied in either patient or control group

n = the number of individuals positive for each antigen

**Table 2. HLA-B frequencies in patients with NPC and healthy controls from Thailand**

| HLA antigen | NPC Patients<br>(N = 53) |       | Controls<br>(N = 70) |       |
|-------------|--------------------------|-------|----------------------|-------|
|             | n                        | AgF % | n                    | AgF % |
| B5 (B51)    | 0                        | 0     | 0                    | 0     |
| B5 (B52)    | 4                        | 7.5   | 5                    | 7.1   |
| B7          | 2                        | 3.8   | 5                    | 7.1   |
| B8          | 0                        | 0     | 1                    | 1.4   |
| B12 (B44)   | 5                        | 9.4   | 14                   | 20    |
| B12 (B45)   | 0                        | 0     | 0                    | 0     |
| B13         | 10                       | 18.8  | 16                   | 22.8  |
| B14         | 0                        | 0     | 1                    | 1.4   |
| B15 (B62)   | 5                        | 9.4   | 7                    | 10    |
| B15 (B75)   | 6                        | 11.3  | 5                    | 7.1   |
| B15 (B76)   | 0                        | 0     | 0                    | 0     |
| B15 (B77)   | 0                        | 0     | 2                    | 2.8   |
| B16 (B38)   | 4                        | 7.5   | 4                    | 5.7   |
| B16 (B39)   | 1                        | 1.8   | 0                    | 0     |
| B17*        | 1                        | 1.8   | 0                    | 0     |
| B17 (B57)   | 2                        | 3.8   | 7                    | 10    |
| B17 (B58)   | 13                       | 24.5  | 8                    | 11.4  |
| B18         | 6                        | 11.3  | 4                    | 5.7   |
| B22 (B54)   | 1                        | 1.8   | 2                    | 2.8   |
| B22 (B55)   | 1                        | 1.8   | 1                    | 1.4   |
| B22 (B56)   | 1                        | 1.8   | 3                    | 4.3   |
| B27         | 1                        | 1.8   | 5                    | 7.1   |
| B35         | 4                        | 7.5   | 9                    | 12.8  |
| B37         | 1                        | 1.8   | 0                    | 0     |
| B40 (B60)   | 10                       | 18.8  | 16                   | 22.8  |
| B40 (B61)   | 4                        | 7.5   | 3                    | 4.3   |
| B42         | 0                        | 0     | 1                    | 1.4   |
| B46         | 16                       | 30.2  | 10                   | 14.2  |

|     |   |     |   |     |
|-----|---|-----|---|-----|
| B47 | 0 | 0   | 0 | 0   |
| B48 | 0 | 0   | 1 | 1.4 |
| B70 | 1 | 1.8 | 0 | 0   |

N = the total number of individuals studied in either patient or control group

n = the number of individuals positive for each antigen

\* Subtype of B17 could not be interpreted in one individual, who has both B15 and B17, because the key sera that differentiate B17 subtype is duo-specific for B15 and B17 subtype (B57).

**Table 3. High resolution HLA-B Allele frequencies in patients with NPC and healthy controls from Thailand**

| HLA-B<br>Ailele | NPC Patients    |      | Controls        |      |
|-----------------|-----------------|------|-----------------|------|
|                 | Count (2N =108) | %    | Count (2N = 98) | %    |
| B*0705/6        | 1               | 1.8  | 2               | 4.0  |
| B*1301          | 4               | 7.4  | 4               | 8.1  |
| B*1302          | 1               | 1.8  | 1               | 2.0  |
| B*1402          | 0               | 0.0  | 1               | 2.0  |
| B*1501          | 3               | 5.5  | 1               | 2.0  |
| B*1502          | 6               | 11.1 | 8               | 16.3 |
| B*1504          | 1               | 1.8  | 0               | 0.0  |
| B*1511          | 1               | 1.8  | 1               | 2.0  |
| B*1517          | 1               | 1.8  | 0               | 0.0  |
| B*1518          | 0               | 0.0  | 1               | 2.0  |
| B*1521          | 0               | 0.0  | 1               | 2.0  |
| B*1525          | 1               | 1.8  | 2               | 4.0  |
| B*1532          | 0               | 0.0  | 1               | 2.0  |
| B*1801          | 1               | 1.8  | 2               | 4.0  |
| B*1802          | 4               | 7.4  | 1               | 2.0  |
| B*2704          | 0               | 0.0  | 2               | 4.0  |
| B*2706          | 0               | 0.0  | 3               | 6.1  |
| B*3501          | 0               | 0.0  | 1               | 2.0  |
| B*3503          | 1               | 1.8  | 1               | 2.0  |
| B*3505          | 1               | 1.8  | 1               | 2.0  |
| B*3701          | 1               | 1.8  | 1               | 2.0  |
| B*38021         | 6               | 11.1 | 2               | 4.0  |
| B*3804          | 0               | 0.0  | 1               | 2.0  |
| B*3901          | 1               | 1.8  | 0               | 0.0  |
| B*3909          | 1               | 1.8  | 3               | 6.1  |
| B*4001          | 13              | 24.1 | 7               | 14.2 |
| B*4002          | 3               | 5.5  | 2               | 4.0  |
| B*4006          | 0               | 0.0  | 2               | 4.0  |
| B*44032         | 6               | 11.1 | 14              | 28.5 |
| B*4601          | 25              | 46.3 | 8               | 16.3 |

|         |   |      |   |      |
|---------|---|------|---|------|
| B*4801  | 1 | 1.8  | 0 | 0.0  |
| B*51011 | 5 | 9.2  | 3 | 6.1  |
| B*51012 | 7 | 12.9 | 0 | 0.0  |
| B*52011 | 3 | 5.5  | 5 | 10.0 |
| B*5502  | 1 | 1.8  | 2 | 4.0  |
| B*5604  | 1 | 1.8  | 0 | 0.0  |
| B*5801  | 7 | 12.9 | 6 | 12.2 |
| B*5401  | 1 | 1.8  | 4 | 8.1  |
| B*5701  | 0 | 0.0  | 3 | 6.1  |
| B*7021  | 0 | 0.0  | 1 | 2.0  |

N = the total number of individuals studied in either patient or control group

**Table 4. HLA class I alleles commonly present in Thai NPC population**

| HLA allele          | Allele frequency in Thai NPC patients |
|---------------------|---------------------------------------|
| HLA-A2 <sup>a</sup> | 58%                                   |
| HLA-A11             | 43%                                   |
| HLA-A24             | 26%                                   |
| HLA-A33             | 32%                                   |
| HLA-B75             | 11%                                   |
| HLA-B44             | 9-11%                                 |
| HLA-B46             | 30-46%                                |
| HLA-B58             | 12-24%                                |
| HLA-B60             | 19-24%                                |

<sup>a</sup>Common HLA-A2 subtypes in Thai population are A\*0203 and A\*0207 (Vejbaesya et al., 1998)

**Table 5. HLA-A and B antigens that demonstrated significant associations with NPC**

| HLA                  | NPC<br>(N = 53) |    | Controls<br>(N = 70) |    | +/-<br>associatio<br>n | p value |
|----------------------|-----------------|----|----------------------|----|------------------------|---------|
|                      | n               | %  | n                    | %  |                        |         |
|                      |                 |    |                      |    |                        |         |
| HLA-A2 <sup>a</sup>  | 31              | 58 | 27                   | 38 | +                      | 0.02    |
| HLA-B46 <sup>b</sup> | 16              | 30 | 10                   | 14 | +                      | 0.03    |

N = the total number of individuals studied in either patient or control group

n = the number of individuals positive for each antigen

<sup>a</sup>  $\chi^2 = 6.4$ ,  $p = 0.02$ , OR = 2.24, 95% CI = 1.02-4.97

<sup>b</sup>  $\chi^2 = 7.9$ ,  $p = 0.03$ , OR = 2.59, 95% CI = 0.98-6.95

**Table 6. HLA-B alleles that demonstrated significant associations with NPC**

| HLA-B*             | NPC      |    | Controls |    | +/-<br>associatio<br>n | p value |
|--------------------|----------|----|----------|----|------------------------|---------|
|                    | (N = 54) |    | (N = 49) |    |                        |         |
|                    | n        | %  | n        | %  |                        |         |
| 44032 <sup>a</sup> | 5        | 9  | 14       | 29 | -                      | 0.01    |
| 4601 <sup>b</sup>  | 21       | 39 | 7        | 14 | +                      | 0.005   |
| 51012 <sup>c</sup> | 6        | 11 | 0        | 0  | +                      | 0.02    |

N = the total number of individuals studied in either patient or control group

n = the number of individuals positive for each allele

<sup>a</sup>  $\chi^2 = 6.4$ ,  $p = 0.01$ , OR = 0.26, 95% CI = 0.07-0.85

<sup>b</sup>  $\chi^2 = 7.9$ ,  $p = 0.005$ , OR = 3.8, 95% CI = 1.34-11.82

<sup>c</sup> Fisher's exact,  $p = 0.02$

**Figure 2. Example of complete sequences of nucleotide bases and amino acids from latent membrane protein-1 (LMP1) gene, CAO strain which is an EBV isolated from NPC biopsy from Chinese patients.**

>gi|11136612|gb|AF304432.1|AF304432 Human herpesvirus 4 latent membrane protein-1 (LMP1) gene, complete cds

ATGGAACGCGACCTTGAGAGGGGGCCACCGGGCCCGCCACGGCCCCCTCTAGGAC  
CCCCCCTCTCCTCTTCCATAGGCCTTGCTCTCCTTCTCCGCTCTTGGCGCTACTGT  
TCTGGCTGTATATCGTTATGAGTGACTGGACTGGAGGAGCGCTCCTTGTCTCTATT  
CCTTTGCTCTCATGCTTATTATTATCATTCTCATCATCTTTATCTTCAGAAGAGACCTT  
CTCTGTCCACTTGGAGGCCTTGGTCTACTCCTACTGATGAGTAAGTATTACACCCTTT  
GCCCCCACCCTTTCCCTTACGCTTCCTTCTCTAACGCACTTTCTCCTCTTTCCCC  
AGTCACCCTCCTACTCATCGCTCTCTGGAATTTGCACGGACAGGCATTGTACCTTGG  
AATTGTGCTGTTTCATCTTTGGCTGCTTACTTGGTAAGATCTAACATTCCCTAGGACTT  
ATTTACCACACCCTCACCTTTCCAGCCCTAACACTCTTTTTTTCAACGCAGTCTTAGG  
TCTCTGGATCTACTTCTTGGAGATTCTCTGGCGGCTTGGTGCCACCCTCTGGCAGCT  
TTTGGCCTTCATCCTAGCCTTCTTCCTAGCCATCATCCTGCTTATTATTGCTCTCTATC  
TACAACAAACTGGTGGACTCTATTGGTTGATCTCCTTTGGCTCCTCCTGTTTATGGC  
CATTTTAATCTGGATGTATTATCATGGACCACGACACACTGATGAACACCACCACGAT  
GACTCCCTCCCGCACCTCAACAAGCTACCGACGATTCTAGCCATGAATCTGACTCT  
AACTCCAACGAGGGCAGACACCACCTGCTCGTGAGTGGGGCCGGCGACGGACCCC  
CACTCTGCTCTCAAACCTAGGCGCACCTGGAGGTGGTCCTGACAATGGCCCACAG  
GACCCTGACAACACTGATGACAATGGCCCACAGGACCCTGACAACACTGATGACAAT  
GGCCCACAGGACCCTGACAACACTGATGACAATGGCCCACAGGACCCTGACAACAC  
TGATGACAATGGCCCACAGGACCCTGACAACACTGATGACAATGGCCCACAGGACC  
CTGACAACACTGATGACAATGGCCCACAGGACCCTGACAACACTGATGACAATGGC  
CCACATGACCCGCTGCCTCATAACCCTAGCGACTCTGCTGGAAATGATGGAGGCCC  
TCCAAATTTGACGGAAGAGGTTGCAAACAAAGGAGGTGACCGGGGGCCCGCCTTCGA  
TGACAGACGGTGGCGGCGGTGATCCACACCTTCCTACGCTGCTTTTGGGTACTTCT  
GGTTCCGGTGGAGATGATGACGACCCCCACGGCCAGTTCAGCTAAGCTACTATGA  
CTAA

>gi|11136612|gb|AAG31283.1|AF304432\_1 latent membrane protein-1 [Human herpesvirus 4]

MERDLERGPPGPPRPPLGPPLSSSIGLALLLLLALLFWLYIVMSDWTGGALLVLYSFAL  
MLIIIIIIIFIFRRDLLCPLGGLGLLLLMITLLLI**ALWNLHGQALYLGIVLFIFGCLLVGLWIYFL**  
**EILWRLGATLWQLLAFILAFFLAIILLIIALYLQQNWWTLLVDLLWLLLFMAILIWMYYHGPR**  
HTDEHHHDDSLPHPQQATDDSSHE**SDSNSNEGRHHLLVSGAGDGPPLCSQNLGAPGG**  
GPDNGPQDPDNTDDNGPQDPDNTDDNGPQDPDNTDDNGPQDPDNTDDNGPQDPDN  
TDDNGPQDPDNTDDNGPQDPDNTDDNGPHDPLPHNPSDSAGNDGGPPNLTEEVANK  
GGDRGPPSMTDGGGGGDPHLPTLLLGTSGSGGDDDDPHGPPVQLSYYD

Note: Bold letters indicate the position of five CTL epitopes described in the sequencing result in this study.

**Table 7. Sequences of HLA class I-restricted LMP1 epitopes in EBV isolates from Thai NPC biopsy compared to various EBV strains characterized previously**

| Virus origin       | Epitope sequence                                         | HLA restriction | Number of isolates |
|--------------------|----------------------------------------------------------|-----------------|--------------------|
| B95.8 <sup>a</sup> | GCC CTC CTT GTC CTC TAT TCC TTT GCT<br>A L L V L Y S F A | HLA-A2          |                    |
| CAO <sup>b</sup>   | -- G -----<br>- - - - -<br>- - - - -                     |                 |                    |
| C15 <sup>c</sup>   | -----<br>- - - - -<br>- - - - -                          |                 |                    |
| Raji <sup>d</sup>  | ----- G -----<br>- - - - - A<br>- - - - -                |                 |                    |
| Thai               | -- G -----<br>- - - - -<br>- - - - -                     |                 | 3                  |
| Thai               | -- G ----- G -----<br>- - - - - A<br>- - - - -           |                 | 2                  |
| B95.8 <sup>a</sup> | CTC CTA CTC ATC GCT CTC TGG AAT TTG<br>L L L I A L W N L | HLA-A2          |                    |
| CAO <sup>b</sup>   | -- G -----<br>- - - - -<br>- - - - -                     |                 |                    |
| C15 <sup>c</sup>   | -----<br>- - - - -<br>- - - - -                          |                 |                    |
| Raji <sup>d</sup>  | ----- G -----<br>- - - - -<br>- - - - -                  |                 |                    |
| Thai               | ----- G ----- G -----<br>- - - - -<br>- - - - -          |                 | 1                  |

|                    |                                                          |                 |                    |
|--------------------|----------------------------------------------------------|-----------------|--------------------|
|                    | -<br>- - - - - S - - -<br>- -                            |                 |                    |
| Thai               | ---<br>- - - - -<br>- -                                  |                 | 1                  |
| B95.8 <sup>a</sup> | TAC TTA TTG GAG ATG CTC TGG CGA CTT<br>Y L L E M L W R L | HLA-A2          |                    |
| CAO <sup>b</sup>   | --- --C --- --T --- --G ---<br>- F - - I - -             |                 |                    |
| C15 <sup>c</sup>   | --- --- --C --T --- ---<br>- - - D I - -                 |                 |                    |
| Raji <sup>d</sup>  | --- --- --- --T --- ---<br>- - - - I - -                 |                 |                    |
| Thai               | --- --C --- --T --- --G ---<br>- F - - I - -             |                 | 1                  |
| Virus origin       | Epitope sequence                                         | HLA restriction | Number of isolates |
| Thai               | --- --C --- --A --T --- --G ---<br>- F - - I - -         |                 | 1                  |
| B95.8 <sup>a</sup> | TCT GAC TCT AAC TCC AAC GAG GGC AGA<br>S D S N S N E G R | HLA-A31/A33     |                    |
| CAO <sup>b</sup>   | ---<br>- - - - -<br>- -                                  |                 |                    |
| C15 <sup>c</sup>   | ---<br>- - - - -<br>- -                                  |                 |                    |

|                    |                                                                            |         |     |
|--------------------|----------------------------------------------------------------------------|---------|-----|
| Raji <sup>d</sup>  | <p>-----</p> <p>- - - - -</p> <p>- -</p>                                   |         |     |
| Thai               | <p>-----</p> <p>- - - - -</p> <p>- -</p>                                   |         | 10  |
| Thai               | <p><b>A</b> -----</p> <p><b>T</b> - - - - -</p> <p>- -</p>                 |         | 1 . |
| B95.8 <sup>a</sup> | <p>AAC GAG GGC AGA CAC CAC CTG CTC GTG</p> <p><b>N E G R H H L L V</b></p> | HLA-B61 |     |
| CAO <sup>b</sup>   | <p>-----</p> <p>- - - - -</p> <p>- -</p>                                   |         |     |
| C15 <sup>c</sup>   | <p>-----</p> <p>- - - - -</p> <p>- -</p>                                   |         |     |
| Raji <sup>d</sup>  | <p>----- <b>t</b> -----</p> <p>- - - - - <b>L</b> - - -</p> <p>- -</p>     |         |     |
| Thai               | <p>-----</p> <p>- - - - -</p> <p>- -</p>                                   |         | 10  |
| Thai               | <p>----- <b>G</b> -----</p> <p>- - - - - <b>R</b> -</p> <p>- -</p>         |         | 1   |

<sup>a</sup> B95.8 is a reference type I EBV strain isolated from a marmoset monkey lymphocyte.

<sup>b</sup> CAO is a strain derived from a Chinese NPC patient.

<sup>c</sup> C15 is a strain derived from a white Mediterranean NPC patient.

<sup>d</sup> Raji is a strain derived from an African Burkitt's lymphoma cell line.

**Table 8. List of donors with HLA types that were included in the overlapping peptide screening test**

| <b>ID</b> | <b>HLA-A</b>    | <b>HLA-B</b>    |
|-----------|-----------------|-----------------|
| <b>PR</b> | <b>A2, A24</b>  | <b>B35, B60</b> |
| <b>NA</b> | <b>A11, A24</b> | <b>B27, B60</b> |
| <b>WI</b> | <b>A24, A33</b> | <b>B13, B44</b> |
| <b>CH</b> | <b>A24</b>      | <b>B56, B75</b> |
| <b>AT</b> | <b>A11, A31</b> | <b>B13, B51</b> |
| <b>PA</b> | <b>A2, A11</b>  | <b>B60</b>      |
| <b>WE</b> | <b>A2, A33</b>  | <b>B44, B46</b> |
| <b>SP</b> | <b>A24, A11</b> | <b>B18, B27</b> |
| <b>SU</b> | <b>A2, A3</b>   | <b>B13, B61</b> |
| <b>SO</b> | <b>A1, A24</b>  | <b>B57, B35</b> |
| <b>AN</b> | <b>A3, A33</b>  | <b>B75, B57</b> |
| <b>SM</b> | <b>A2</b>       | <b>B57</b>      |
| <b>PO</b> | <b>A24</b>      | <b>B27, B60</b> |
| <b>SA</b> | <b>A11</b>      | <b>B27</b>      |
| <b>CA</b> | <b>A11, A33</b> | <b>B44, B61</b> |
| <b>OR</b> | <b>A2, A33</b>  | <b>B51, B58</b> |
| <b>SB</b> | <b>A11, A33</b> | <b>B44, B52</b> |
| <b>IN</b> | <b>A11, A24</b> | <b>B35, B38</b> |
| <b>KA</b> | <b>A11, A26</b> | <b>B8, B60</b>  |
| <b>UB</b> | <b>A11, A26</b> | <b>B52, B58</b> |
| <b>PN</b> | <b>A2, A24</b>  | <b>B27, B52</b> |

**Table 9. Summarized result of the overlapping peptide screening from LMP1 sequences**

| <b>ID</b> | <b>HLA-A</b>    | <b>HLA-B</b>    | <b>peptide</b>            | <b>ELISPOT result<br/>(SFC/ million)</b> |
|-----------|-----------------|-----------------|---------------------------|------------------------------------------|
| <b>AT</b> | <b>A11, A31</b> | <b>B13, B51</b> | <b>Peptide#28:</b>        | <b>60</b>                                |
|           |                 |                 | <b>SNSNEGRHHLLVSGAGDD</b> | <b>.</b>                                 |
|           |                 |                 | <b>SDSNSNEGR</b>          | <b>0</b>                                 |
|           |                 |                 | <b>NEGRHHLLV</b>          | <b>0</b>                                 |
| <b>SP</b> | <b>A24, A11</b> | <b>B18, B27</b> | <b>Peptide#28:</b>        | <b>20</b>                                |
|           |                 |                 | <b>SNSNEGRHHLLVSGAGDD</b> |                                          |
|           |                 |                 | <b>SDSNSNEGR</b>          | <b>0</b>                                 |
|           |                 |                 | <b>NEGRHHLLV</b>          | <b>0</b>                                 |

**SFC = spot forming cell**

**Table 10. List of potential epitopes predicted by “Binding Motif Scanner” in HLA molecular Immunology database**

| <b>HLA<br/>(Serotype)</b> | <b>HLA<br/>(Genotype)</b> | <b>Motif</b>               | <b>Potential epitopes</b>                                                                                                                                                        |
|---------------------------|---------------------------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>A11</b>                | <b>A*1101</b>             | <b>XXXXXXXXX[K]</b>        | <b>NLTEEVANK</b>                                                                                                                                                                 |
| <b>A24</b>                | <b>-</b>                  | <b>X[Y]XXXXXXXX[I,L,F]</b> | <b>LYSFALMLI</b><br><b>LYLGIVLFI</b>                                                                                                                                             |
| <b>A31</b>                | <b>A*3101</b>             | <b>XXXXXXXXX[R]</b>        | <b>ERGPPGPPR</b><br><b>ILIIIFIFR</b><br><b>ILIIIFIFRR</b><br><b>IYFLEILWR</b><br><b>IWMYYHGPR</b><br><b>SDSNSNEGR</b><br><b>EVANKGGDR</b>                                        |
| <b>B27</b>                | <b>-</b>                  | <b>X[R]XXXXXXXX</b>        | <b>ERDLERGPP</b><br><b>ERGPPGPPR</b><br><b>PRPPLGPPL</b><br><b>FRRDLLCPL</b><br><b>RRDLLCPLG</b><br><b>WRLGATLWQ</b><br><b>PRHTDEHHH</b><br><b>GRHHLLVSG</b><br><b>DRGPPSMTD</b> |
| <b>B51</b>                | <b>B*5101</b>             | <b>X[A,P,G]XXXXXX[F,I]</b> | <b>LGPPLSSSI</b><br><b>LALLFWLYI</b><br><b>GALLVLYSF</b><br><b>FALMLIII</b><br><b>HGQALYLG I</b>                                                                                 |
|                           | <b>B*5102</b>             | <b>X[A,P,G]XXXXXX[V,I]</b> | <b>LGPPLSSSI</b><br><b>LALLFWLYI</b><br><b>FALMLIII</b><br><b>HGQALYLG I</b>                                                                                                     |

---

|               |                             |                  |
|---------------|-----------------------------|------------------|
|               |                             | <b>GPPNLTEEV</b> |
| <b>B*5103</b> | <b>X[A,P,G]XXXXX[V,F,I]</b> | <b>GPPLSSSI</b>  |
|               |                             | <b>FALMLIII</b>  |
|               |                             | <b>LGLLLLMI</b>  |
|               |                             | <b>QALYLGIV</b>  |
|               |                             | <b>LGIVLFIF</b>  |
|               |                             | <b>LAFILAFF</b>  |
|               |                             | <b>LAFFLAII</b>  |
|               |                             | <b>LAIIILLI</b>  |
|               |                             | <b>EGRHHLLV</b>  |
|               |                             | <b>PPNLTEEV</b>  |

---

Note: Bold letters indicate the potential epitopes since they are located within peptide#28.

## DISCUSSION

HLA distribution data from Thai NPC patients is useful since vaccine development including T cell epitopes restricted to these common alleles will benefit the majority of affected population. As demonstrated in this study, HLA typing data was helpful in the process of selecting donors as listed in table 8. Interestingly, the frequencies of certain HLA alleles were significantly different between NPC patient and normal control group. In conclusion, this study reported 2 susceptible, A2 and B46 antigens, for NPC in Thai population. In the allelic level a protective B\*44032 allele and two susceptible, B\*4601 and B\*51012 alleles, were also identified for Thai NPC population.

A lower incidence of B\*44032 in the patient group was noticed (9 vs. 29%,  $p < 0.01$ ) similar to a previous report in East Africa in which B44, characterized by serological typing, was reported as a resistance antigen in NPC (Moore et al., 1983). Interestingly, some CTL epitopes from EBV antigens have been identified as restricted by B44 (Khanna et al., 1997). Studies of those epitopes that contributing to the protective effect of the protective allele might be useful in vaccine development. The frequencies of another two alleles, B\*4601 and B\*51012, were significantly increased in NPC patients (39 and 11% vs. 14 and 0%,  $p < 0.005$  and  $p < 0.02$ , respectively). As mentioned above, the association with B46 has been consistently observed in Chinese populations (reviewed in Ren and Chan, 1996; Simons et al., 1974 and 1975; Chan et al., 1983 and 1985). One previous report of 20 Thai NPC patients also demonstrated a positive association of NPC with B46 ( $p < 0.05$ ) (Chan et al., 1985). Our study has confirmed that result suggesting that genetic susceptibility of NPC to in the Thai population is likely similar to the Chinese population. The restricted-antigen binding properties of the B\*4601 molecule (Barber et al., 1996) might be one explanation for its link to susceptibility to NPC. Interestingly, no EBV epitopes restricted by B46 have been reported so far and further studies are required to prove this hypothesis. Although there are some relationships between HLA types and NPC, the exact nature of this association is not yet clear. It is more likely that HLA antigens are not involved in the causation of the disease but are very closely linked to the "disease susceptibility genes". In fact, many studies supported this latter theory (Lu et al., 1990; Ooi et al., 1997). However, no major susceptibility genes of NPC have been identified so far.

Previous studies have suggested that LMP1 sequences in different geographic regions of the world display a very high degree of variation. This genetic variation has been considered as a major impediment towards the use of LMP1 as a potential immunotherapeutic target for the treatment of relapsed NPC. Hence it was important to determine the extent to which the B95.8 derived LMP1 epitope sequences are conserved in EBV isolates from different geographic regions of the world. Studying a panel of EBV isolates representative from African (Raji) and Chinese NPC (CAO, C15) as well as Thai NPC biopsies, we found that T cell epitope sequences from LMP1 were generally well conserved. Four of the five epitopes sequenced here showed only minor sequence variation. However, some unique nucleotide substitution which resulted in amino acid substitution were identified from Thai NPC isolates within these relatively conserved epitopes. Although the effect of these changes against CTL activity remains to be further investigated. These findings stress the necessitation of specific epitope characterization from each endemic area.

The only epitope with major sequence divergence was the HLA A2 supertype-restricted YLLEMLWRL epitope, which displayed an interesting pattern of sequence diversity in EBV isolates from different geographic regions. The analysis of the genetic variants of the YLLEMLWRL epitope indicated that the variant sequence (YFLEILWRL) is prevalent in South-East Asia. Although the precise reason/mechanism for such a high degree of genetic variation within this epitope is not known, it is possible that mutation within this epitope in the isolates from South-East Asia, where NPC is endemic, may provide an advantage in protecting these isolates from the EBV-specific CTL response.

A low frequency of positive responses against LMP1 have been reported in several studies (Khanna et al., 1998; Leen et al., 2001; Meij et al., 2002; Whitney et al., 2002). Recent study by Meij et al., 2002 using the same strategy of overlapping peptide screening in healthy Caucasian donors detected positive response only in 9 out of 50 donors (18%). In addition, the number of cells reactive to LMP1 were very low similar to our study. In summary, this protein is poorly immunogenic. The explanation for this weakly immunogenic is not understood. It is possible that LMP1 may has immunosuppressive properties that favor the induction of T cell anergy (Dukers et al.,

2000). However, to target EBV-positive NPC tumor, such small response against LMP1 should be amplified, either by active immunization or by *in vitro* expansion and re-infusion. Therefore, more donors should be included to obtain more putative CTL epitopes of LMP1.

## **SUGGESTION FOR FURTHER WORK**

Further identification of novel CTL epitopes from LMP1 using a larger panel of donor should be pursued with the use of bioinformatic technology e.g., binding motif scanner. The characterization CTL epitopes in Thai population from other candidate protein such as LMP2 is also needed by applying the same strategy as this study. In addition, increasing interest has been focusing on T helper epitopes as well since the addition of T helper epitope with CTL epitopes should increase the efficiency of the immunotherapy. Therefore, the characterization of T helper epitopes restricted to common HLA class II alleles is another subject of interest for future work.

## REFERENCES

1. Barber LD, Percival L, Valiante NM, et al. (1996) The inter-locus recombination HLA-B\*4601 has high selectivity in peptide binding and functions characteristic of HLA-C. *J Exp Med* 184(2): 735-740.
2. Busson P, Edwards RH, Tursz T, Raab-Traub N (1995) Sequence polymorphism in the Epstein-Barr virus latent membrane protein (LMP)-2 gene. *J Gen Virol* 76 ( Pt 1):139
3. Chan SH, Day NE, Kunaratnam N, Chia KB, Simons MJ. (1983) HLA and nasopharyngeal carcinoma in Chinese – A further study. *Br J Cancer* 32(2): 171-176
4. Chan SH, Chew CT, Prasad U, Wee GB, Srinivasan N, Kunaratnam N. (1985) HLA and nasopharyngeal carcinoma in Malays. *Br J Cancer*. 51(3): 389-392
5. Dukers DF, Meij P., Vervoort MBHJ, et al. (2000) Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. *J Immunol* 165: 663-70.
6. Heslop HE, Rooney CM (1997) Adoptive cellular immunotherapy for EBV lymphoproliferative disease. *Immunol Rev* 157:217
7. Hu LF, Zabarovsky ER, Chen F, Cao SL, Ernberg I, Klein G, Winberg G (1991) Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. *J Gen Virol* 72 ( Pt 10):2399
8. Khanna R, Burrows SR, Moss DJ (1995) Immune regulation in Epstein-Barr virus-associated diseases. *Microbiol Rev* 59:387.
9. Khanna R, Slade RW, Poulsen L, Moss DJ, Burrows SR, Nicholls J, Burrows JM (1997) Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift. *J Virol* 71:8340.
10. Khanna R, Burrows SR, Neisig A, Neefjes J, Moss DJ, Silins SL (1997) Hierarchy of Epstein-Barr virus-specific cytotoxic T-cell responses in individuals carrying different

subtypes of an HLA allele: implications for epitope-based antiviral vaccines. *J Virol* 71:7429.

11. Khanna R, Burrows SR, Nicholls J, Poulsen LM (1998b) Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. *Eur J Immunol* 28:451.
12. Khanna R, Moss DJ, Burrows SR (1999) Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. *Immunol Rev* 170:49.
13. Khanna R, Burrows SR (2000) Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. *Annu Rev Microbiol* 54:19.
14. Kieff E. Epstein-Barr Virus and its Replication. In: Fields BN, Knipe DM, Howley PM, eds. *Virology*. 3<sup>rd</sup> ed. Philadelphia-New York: Lippincott-Raven publishers, 1996: 2343-2396
15. Krausa P, Brywka M, Savage D, Hui KM, Bunce M, Ngai JL, Teo DL, Ong YW, Barouch D, Allsop CE (1995) Genetic polymorphism within HLA-A\*02: significant allelic variation revealed in different populations. *Tissue Antigens* 45:223.
16. Leen A, Meij P, Redchenko I et al. (2001) Differential immunogenicity of Epstein-Barr virus latent cycle proteins for human CD4<sup>+</sup> T-helper 1 responses. *J Virol* 75:8649-56.
17. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, Masucci MG (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. *Nature* 375:685.
18. Lu SJ, Day NE, Degos L, et al. (1990) Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. *Nature* 346(6283): 470-471.
19. Meij P, Leen A, Rickinson AB, et al. (2002). Identification and prevalence of CD8<sup>+</sup> T cell response directed against Epstein Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. *Int J Cancer* 99:93-99

20. Miller WE, Edwards RH, Walling DM, Raab-Traub N (1994) Sequence variation in the Epstein-Barr virus latent membrane protein 1. *J Gen Virol* 75 ( Pt 10):2729.
21. Moore SB, Pearson GR, Nell HB, Weiland LH. (1983) HLA and nasopharyngeal carcinoma in North American Caucasoids. *Tissue Antigens* 22(1): 72-75
22. Moss DJ, Chan SH, Burrows SR, Chew TS, Kane RG, Staples JA, Kunaratnam N (1983) Epstein-Barr virus specific T-cell response in nasopharyngeal carcinoma patients. *Int J Cancer* 32:301.
23. Mutirangura A, Tanunyutthawongese, Pornthanakasem W, et al. (1997) Genomic alterations in nasopharyngeal carcinoma: loss of heterozygosity and Epstein-Barr virus infection. *Br J Cancer* 76: 770-776.
24. Mutirangura A, Pornthanakasem W, Theamboonlers A, et al. (1998) Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. *Clinical Cancer Research* 4: 665-669.
25. Ooi EE, Ren EC, Chan SH. (1997) Association between microsatellites within the human MHC and nasopharyngeal carcinoma. *Int J Cancer* 74(2): 229-232.
26. Pimthanotai N, Rizzuto GA, Slack R, et al. (2000) The diversity of alleles encoding HLA-B40: the relative frequencies in US populations and description of 5 novel alleles. *Hum Immunol* 61: 808-815.
27. Ren EC, Chan SH. (1996) Human leukocyte antigens and nasopharyngeal carcinoma. *Clin Science* 91(3): 256-258
28. Rickinson AB, Moss DJ (1997) Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. *Annu Rev Immunol* 15:405.
29. Rooney CM, Roskrow MA, Suzuki N, Ng CY, Brenner MK, Heslop H (1993) Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. *Ann Oncol* 9 Suppl 5:S129.
30. Simons MJ, Day NE, Wee GB, et al. (1974) Nasopharyngeal carcinoma V. Immunogenetic studies of Southeast Asian ethnic groups with high and low risk for the tumor. *Cancer Research* 34(5): 1192-1195

31. Simon MJ, Wee GB, Chan SH, Shanmugaratnam K, Day NE, de The GB. (1975) Probable identification of an HL-A second locus antigen associated with a high risk of nasopharyngeal carcinoma. *Lancet* 1(7899): 142-3
32. Vejbaesya S, Eiermann TH, Suthipinittharm P, Bancha C, Stephens HA, Luangtrakool K, Chandanayingyong D (1998) Serological and molecular analysis of HLA class I and II alleles in Thai patients with psoriasis vulgaris. *Tissue Antigens* 52:389.
33. Walling DM, Shebib N, Weaver SC, Nichols CM, Flaitz CM, Webster-Cyriaque J (1999) The molecular epidemiology and evolution of Epstein-Barr virus: sequence variation and genetic recombination in the latent membrane protein-1 gene. *J Infect Dis* 179:763.
34. Whitney BM, Chan ATC, Rickinson AB, Lee SP, Lin CK, Johnson PJ (2002) Frequency of EBV-specific CTL in the blood of Southern Chinese blood donors and NPC patients. *J Med Virol* 67:359-363.

## OUTPUT จากโครงการวิจัยที่ได้รับทุนจากสกว.

### 1. ผลงานตีพิมพ์ในวารสารวิชาการนานาชาติ

- Pimtanonthai N, Charoenwongse P, Mutirangura A, Hurley CK. "Distribution of HLA-B alleles in nasopharyngeal carcinoma patients and normal controls in Thailand." Tissue Antigens 2002; 59: 223-225

นอกเหนือจากผลงานตีพิมพ์ที่ได้จากโครงการนี้แล้ว ตัวอย่าง DNA จากผู้ป่วยมะเร็งโพรงหลังจมูกจากโครงการนี้ยังถูกนำไปใช้ศึกษาในโครงการวิจัยอื่น และมีผลงาน คือ

- Hirankarn (Pimtanonthai) N., Kimkong I, Mutirangura A. "HLA-E and genetic susceptibility to nasopharyngeal carcinoma" Manuscript in Preparation (Plan to submit to Tissue Antigen)

### 2. การเสนอผลงานในที่ประชุมวิชาการ

- Pimtanonthai NH, Kimkong I, Mutirangura A 2002 HLA-E polymorphism in Thai patients with nasopharyngeal carcinoma FIMSA Advanced course and conference on "Molecular Mechanisms of Infection and Immunity" Ayuthaya, Thailand. October 23, 2002.

## APPENDIX

J. Pimthanotai  
P. Charoenwongse  
A. Mutirangura  
C.K. Hurley

## Distribution of HLA-B alleles in nasopharyngeal carcinoma patients and normal controls in Thailand

**Key words:**  
HLA-B, nasopharyngeal carcinoma

**Acknowledgments:**

The authors are deeply indebted to the staff of the Department of Otolaryngology and the Radiotherapy section, Department of Radiology, Chulalongkorn University, for the recruitment of patients and collection of materials. We also thank Mrs Ratchada Intwatana for DNA preparation. This work was supported by the Molecular Biology Research Fund, Faculty of Medicine, Chulalongkorn University, the Thailand Research Fund, and US office of Naval research N00014-94-0049.

**Abstract:** HLA-B frequencies in 54 unrelated nasopharyngeal carcinoma (NPC) patients and 49 healthy random controls in Thailand were investigated by direct DNA sequencing. Similar to previous reports in Chinese NPC patients, HLA-B\*4601 was observed at a greater frequency in patients (21/54 (40%)) compared to controls (7/49 (14%)). An increase in HLA-B\*51012 was also demonstrated. B\*51012 was present in 6/54 (11%) NPC patients but was not observed (0%) in controls. B\*44032 was associated with a decreased risk. Five out of 54 (9%) NPC patients had B\*44032 compared to 14/49 (29%) in the control group.

Nasopharyngeal carcinoma (NPC) is a tumor affecting the epithelial lining in the head and neck region. It is one of the most common cancers in Asia, with the highest incidence rate in South China and intermediate incidence rate in South-east Asia (1). This tumor is quite rare in the Western population. Multiple factors have been reported to be involved in the pathogenesis of this disease including EBV infection, environmental carcinogens (e.g., cigarette smoke, certain foods), and genetic factors (2). HLA is one of the genetic factors reported as having a significant association with NPC (1). Certain HLA antigens or haplotypes, mostly identified using serological techniques, have been associated with either increased or decreased risk in various studies. For example, HLA-A2/B46 haplotypes were consistently reported to be positively associated with NPC in Chinese populations living in different countries (e.g., Singapore, China, Hong Kong, Malaysia, California, U.S.A) (1, 3–6). HLA-B58 is another NPC-associated antigen observed at a higher frequency in Chinese and Malay patients (7) while HLA-A11 was observed at a lower frequency among Chinese NPC patients (6, 7). Studies of HLA in other low incident populations gave more variable results (8–12).

The underlying mechanisms of these associations have not been elucidated. One explanation is the existence of an NPC susceptible gene closely linked to the HLA region which was suggested from an

**Authors' affiliations:**

N. Pimthanotai<sup>1</sup>,  
P. Charoenwongse<sup>1</sup>,  
A. Mutirangura<sup>2</sup>,  
C.K. Hurley<sup>3</sup>

<sup>1</sup>Immunology Unit,  
Department of Microbiology,

<sup>2</sup>Genetics Unit, Department  
of Anatomy, Faculty of  
Medicine, Chulalongkorn  
University, Bangkok,  
Thailand.

<sup>3</sup>Department of Microbiology  
and Immunology,  
Georgetown University,  
Washington, DC, USA

**Correspondence to:**  
Nattaya Pimthanotai,  
Immunology Unit,  
Department of Microbiology,  
Faculty of Medicine,  
Chulalongkorn University,  
Rama IV road, Bangkok  
10330, Thailand  
Tel: 662 256 4132  
Fax: 662 252 5952  
e-mail:  
Nattaya.p@hotmail.com

Received 4 October 2001, revised 14 February 2002,  
accepted for publication 18 February 2002

Copyright © Blackwell Munksgaard 2002  
Tissue Antigens 0001 2815

Tissue Antigens 2002 59: 223–225  
Printed in Denmark. All rights reserved

HLA-B allele frequencies in patients with NPC and healthy controls from Thailand

| HLA-B Allele | NPC Patients     |      | Controls        |      |
|--------------|------------------|------|-----------------|------|
|              | Count (2N = 108) | %    | Count (2N = 98) | %    |
| B*0705/6     | 1                | 1.8  | 2               | 4.0  |
| B*1301       | 4                | 7.4  | 4               | 8.1  |
| B*1302       | 1                | 1.8  | 1               | 2.0  |
| B*1402       | 0                | 0.0  | 1               | 2.0  |
| B*1501       | 3                | 5.5  | 1               | 2.0  |
| B*1502       | 6                | 11.1 | 8               | 16.3 |
| B*1504       | 1                | 1.8  | 0               | 0.0  |
| B*1511       | 1                | 1.8  | 1               | 2.0  |
| B*1517       | 1                | 1.8  | 0               | 0.0  |
| B*1518       | 0                | 0.0  | 1               | 2.0  |
| B*1521       | 0                | 0.0  | 1               | 2.0  |
| B*1525       | 1                | 1.8  | 2               | 4.0  |
| B*1532       | 0                | 0.0  | 1               | 2.0  |
| B*1801       | 1                | 1.8  | 2               | 4.0  |
| B*1802       | 4                | 7.4  | 1               | 2.0  |
| B*2704       | 0                | 0.0  | 2               | 4.0  |
| B*2706       | 0                | 0.0  | 3               | 6.1  |
| B*3501       | 0                | 0.0  | 1               | 2.0  |
| B*3503       | 1                | 1.8  | 1               | 2.0  |
| B*3505       | 1                | 1.8  | 1               | 2.0  |
| B*3701       | 1                | 1.8  | 1               | 2.0  |
| B*38021      | 6                | 11.1 | 2               | 4.0  |
| B*3804       | 0                | 0.0  | 1               | 2.0  |
| B*3901       | 1                | 1.8  | 0               | 0.0  |
| B*3909       | 1                | 1.8  | 3               | 6.1  |
| B*4001       | 13               | 24.1 | 7               | 14.2 |
| B*4002       | 3                | 5.5  | 2               | 4.0  |
| B*4006       | 0                | 0.0  | 2               | 4.0  |
| B*44032      | 6                | 11.1 | 14              | 28.5 |
| B*4601       | 25               | 46.3 | 8               | 16.3 |
| B*4801       | 1                | 1.8  | 0               | 0.0  |
| B*51011      | 5                | 9.2  | 3               | 6.1  |
| B*51012      | 7                | 12.9 | 0               | 0.0  |
| B*52011      | 3                | 5.5  | 5               | 10.0 |
| B*5502       | 1                | 1.8  | 2               | 4.0  |
| B*5604       | 1                | 1.8  | 0               | 0.0  |
| B*5801       | 7                | 12.9 | 6               | 12.2 |
| B*5401       | 1                | 1.8  | 4               | 8.1  |
| B*5701       | 0                | 0.0  | 3               | 6.1  |
| B*7021       | 0                | 0.0  | 1               | 2.0  |

N = the total number of individuals studied in the patient or control group

Table 1

HLA-B alleles that demonstrated significant associations with NPC

| HLA-B*             | NPC (N = 54) |    | Controls (N = 49) |    | ± association | P-value |
|--------------------|--------------|----|-------------------|----|---------------|---------|
|                    | n            | %  | n                 | %  |               |         |
| 44032 <sup>a</sup> | 5            | 9  | 14                | 29 | -             | 0.01    |
| 4601 <sup>b</sup>  | 21           | 39 | 7                 | 14 | +             | 0.005   |
| 51012 <sup>c</sup> | 6            | 11 | 0                 | 0  | +             | 0.02    |

N = the total number of individuals studied in either patient or control group

n = the number of individuals positive for each allele

<sup>a</sup> $\chi^2 = 6.4$ ,  $P = 0.01$ , OR = 0.26, 95% CI = 0.07-0.85<sup>b</sup> $\chi^2 = 7.9$ ,  $P = 0.005$ , OR = 3.8, 95% CI = 1.34-11.82<sup>c</sup>Fisher's exact,  $P = 0.02$ 

Table 2

HLA study of 30 sibling pairs (13). A more recent study, using micro-satellite markers, predicted that this putative NPC susceptible gene, not yet identified, is close to the D6S1624 marker (14). However, the ability of certain HLA molecules to present EBV antigens might also contribute to the observed HLA associations. Moreover, with the increasing interest in epitope-based immunotherapy in EBV-related tumors including NPC, the distribution of HLA alleles in NPC populations will provide useful information for epitope selection i.e., by including the epitopes restricted to common HLA allelic products in the target population. In this study, we investigated the distribution of HLA-B alleles in Thai NPC patients compared to normal controls to identify the HLA-B alleles associated with NPC in Thailand.

The study population included 54 unrelated Thai patients with histologically confirmed NPC diagnosed at King Chulalongkorn Memorial Hospital in Bangkok. There were 34 men and 20 women, with a median age of 48 years (range 16-81 years). All of these patients were positive for the EBNA1 gene in tumor cells as detected by PCR, as reported previously (15, 16). Forty-nine healthy unrelated Thai individuals served as ethnically and geographically matched controls. All patients and controls were typed for the HLA-B locus by direct sequencing of the PCR products using primers BIN1-TA, BIN1-CG and BIN3, which amplified exons 2 and 3 and intron 2 as previously described (17, 18). The allele frequencies were determined by direct counting based on the assumption that individuals carrying a single allele were homozygous. The significance of differences between the two groups was analyzed by the chi-square test. Fisher's exact tests were applied if the expected frequency was less than 5.

The distribution of HLA-B alleles between the two groups is shown in Table 1. A total of 34 HLA-B alleles was observed in the Thai control group, including one new allele (B\*3804) (19). The five most common alleles in Thai controls were B\*44032 (28.5%), B\*4601 (16.3%), B\*1502 (16.3%), B\*4001 (14.2%) and B\*5801 (12.2%). Twenty-nine alleles were detected in NPC patients with the same five common alleles.

observed at high frequencies (11.1–46.3%). In addition, the allele frequencies of B\*38021 (11.1%) and B\*51012 (12.9%) were high in the patient group compared to controls. This information is useful as vaccine development including T cell epitopes restricted to these common alleles will benefit the majority of affected population. When the frequency of HLA-B alleles in NPC patients and normal individuals was compared, significant associations between NPC and three HLA-B alleles were observed, as summarized in Table 2. Specifically, a lower incidence of B\*44032 was noticed in the patient group (9 vs 29%,  $P < 0.01$ ) which was similar to a previous report in East Africa, in which B44, characterized by serological typing, was reported as a resistance antigen in NPC (10). Interestingly, some CTL epitopes from EBV antigens have been identified as restricted by B44 (20). Studies of these epitopes that contribute to the protective effect of the protective allele might be useful in vaccine development. The frequencies of another two alleles, B\*4601 and B\*51012, were significantly increased in NPC patients (39 and 11% vs 14 and 0%,  $P < 0.005$  and  $P < 0.02$ ,

respectively). As mentioned above, the association with B46 has been consistently observed in Chinese populations (1, 3–6). One previous report of 20 Thai NPC patients also demonstrated a positive association of NPC with B46 ( $P < 0.05$ ) (6). Our study has confirmed that genetic susceptibility of NPC to in the Thai population is likely to be similar to the Chinese population. The restricted-antigen binding properties of the B\*4601 molecule (21) might be one explanation for its link to susceptibility to NPC. Interestingly, no EBV epitopes restricted by B46 have been reported so far and further studies are required to prove this hypothesis. No association with B58 was demonstrated in this study; however, in a previous study, B58 association was only seen in newly diagnosed patients and its frequency is very low in long-term survivors (1), which were not identified in this study.

In conclusion, this study reported a protective B\*44032 allele and two susceptible alleles, B\*4601 and B\*51012, for NPC in Thai population.

## References

- Ren EC, Chan SH. Human leukocyte antigens and nasopharyngeal carcinoma. *Clin Sci* 1996; 91: 256–8.
- Lam K, Crawford DH. Epstein-Barr virus and associated diseases. In: Cook GC, ed. *Manson's Tropical Disease*. London: W.B. Saunders Company Ltd, 1996: 696–99.
- Simons MJ, Day NE, Wee GB et al. Nasopharyngeal carcinoma V: Immunogenetic studies of Southeast Asian ethnic groups with high and low risk for the tumor. *Cancer Res* 1974; 34: 1192–5.
- Simon MJ, Wee GB, Chan SH, Shanmugaratnam K, Day NE, de The GB. Probable identification of an HLA-A second locus antigen associated with a high risk of nasopharyngeal carcinoma. *Lancet* 1975; i: 142–3.
- Chan SH, Day NE, Kunaratnam N, Chia KB, Simons MJ. HLA and nasopharyngeal carcinoma in Chinese – A further study. *Br J Cancer* 1983; 32: 171–6.
- Chan SH, Chew CT, Chandanayong D et al. Nasopharyngeal carcinoma: joint report. In: Aizawa M, ed. *HLA in Asia-Oceania*. Sapporo: Hokkaido University Press, 1986: 657–8.
- Chan SH, Chew CT, Prasad U, Wee GB, Srinivasan N, Kunaratnam N. HLA and nasopharyngeal carcinoma in Malays. *Br J Cancer* 1985; 51: 389–92.
- Hall PJ, Levin AG, Entwistle CC et al. HLA antigens in East Africa Black patients with Burkitt's lymphoma or nasopharyngeal carcinoma and in controls: a pilot study. *Hum Immunol* 1982; 5: 91–105.
- Herail P, Tursz T, Guillard MY et al. HLA-A, -B, and -DR antigens in North African patients with nasopharyngeal carcinoma. *Tissue Antigens* 1983; 22: 335–41.
- Moore SB, Pearson GR, Nell HB, Welland LH. HLA and nasopharyngeal carcinoma in North American Caucasoids. *Tissue Antigens* 1983; 22: 72–5.
- Levine PH, Pocinski AG, Madigan P, Bale S. Familial nasopharyngeal carcinoma in patients who are not Chinese. *Cancer* 1992; 70: 1024–9.
- Daniilidis M, Fountzilas G, Fleva A, Daniilidis J, Tourkantonis A. Haplotypes of human leukocyte antigens among patients with nasopharyngeal cancer in Greece. *Oncology* 1997; 54: 185–92.
- Lu SJ, Day NE, Degos L et al. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. *Nature* 1990; 346: 470–1.
- Ooi EE, Ren EC, Chan SH. Association between microsatellites within the human MHC and nasopharyngeal carcinoma. *Int J Cancer* 1997; 74: 229–32.
- Mutirangura A, Tanumyutthawongse Pornthanakasem W et al. Genomic alterations in nasopharyngeal carcinoma: loss of heterozygosity and Epstein-Barr virus infection. *Br J Cancer* 1997; 76: 770–6.
- Mutirangura A, Pornthanakasem W, Theamboonlers A et al. Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma. *Clin Cancer Res* 1998; 4: 665–9.
- Steiner N, Ng J, Bush J, Hartzman RJ, Johnston-Dow L, Hurley CK. HLA-B alleles associated with the B15 serologically defined antigens. *Hum Immunol* 1997; 56: 84–93.
- Pimthanotai N, Rizzuto GA, Slack R et al. The diversity of alleles encoding HLA-B\*40: the relative frequencies in US populations and description of 5 novel alleles. *Hum Immunol* 2000; 61: 805–15.
- Steiner N, Gans CP, Kosman C et al. Novel HLA-B alleles associated with antigens in the 8C CREG. *Tissue Antigens* 2001; 57: 373–5.
- Khanna R, Burrows SR, Nersis A et al. Hierarchy of Epstein-Barr virus-specific cytotoxic T-cell responses in individuals carrying different subtypes of an HLA allele: implications for epitope-based antiviral vaccines. *J Virol* 1997; 71: 7429–35.
- Barber LD, Percival L, Teasdale NM et al. The inter-locus recombination HLA-B\*4601 has high selectivity in peptide binding and functions characteristic of HLA-B. *J Exp Med* 1996; 184: 735–40.

## **HLA-E and genetic susceptibility to nasopharyngeal carcinoma**

Short Title: HLA-E and nasopharyngeal carcinoma

Nattiya (Pimtanothai) Hirankarn<sup>1</sup>, Ingorn Kimkong<sup>2</sup>, Apiwat Mutirangura<sup>3</sup>

<sup>1</sup>Department of Microbiology, Faculty of Medicine, <sup>2</sup>Inter-Department of Medical Microbiology, Graduate School, <sup>3</sup>Department of Anatomy, Chulalongorn University, Thailand.

### **Abstract**

Nasopharyngeal carcinoma (NPC) has been known to be associated with HLA class I region. The aim of this study was to investigate the association between HLA-E and genetic susceptibility to nasopharyngeal carcinogenesis by comparing the frequencies of HLA-E alleles in 104 Thai patients with NPC and 100 healthy controls. HLA-E typing was performed using PCR-SSOP method. DNA sequencing was used to confirm the accuracy of PCR-SSOPs results. The frequency of the HLA-E\*0103, 0103 genotype, but not others, was increased in the patients compared to controls ( $p = 0.0141$ , OR = 2.11, 95% CI = 1.15-3.88). A significant increase in the frequency of the HLA-E\*0103 allele was found in the patients compared to normal controls ( $p = 0.0076$ , OR = 1.78, 95% CI = 1.16-2.74). These might suggest a possible important role for HLA-E in NPC development, possibly via NK cell or CTL function.

**Key words:** Nasopharyngeal carcinoma; HLA class I; HLA-E; PCR-SSOP; NK cell; CTL cell

## Introduction

Nasopharyngeal carcinoma (NPC) is a geographically restricted tumor of epithelial cell lining nasopharynx (1,2). The tumor is rare among European and North American Caucasians (less than 1 per 100,000). However, it is more common in many Asian countries, especially common in Southern China (30 - 50 per 100,000) (3). The etiologic factors identified for NPC include environmental and genetic factors. Implicated environmental factors include the Epstein Barr virus, nutritional factors, and exposure to smoke, wood dust and aromatic hydrocarbon (4-6). The data of different incidence among different populations as well as the high incidence among migrants and family clustering suggested the involvement of genetic factors in addition to environmental factor (7-9). HLA associations have been reported in NPC. Several studies have been reported that HLA-A2, HLA-B46, HLA-B58 and HLA-B\*51012 were associated with NPC (1,2,7). However, The explanations of these associations are still unclear. Another possibility is that there may be another disease susceptibility gene that linked to the HLA-A and HLA-B genes. This latter hypothesis was further strengthened by Lu and coworker in 1990 who conducted a linkage study based on affected sib-pair in Chinese population which suggests that, a gene closely linked to the HLA locus confers a greatly increased risk of nasopharyngeal carcinoma (11). Since the suspected gene is around the HLA region, Ooi and co-workers began mapping the approximate position of a gene closely linked to the HLA region. In that study, they found that NPC susceptibility gene may be within the centromeric end of the class I and the telomeric end of class III regions of HLA, near the D6S1624 microsatellite locus (12). In our study, we are interested in the HLA-E gene that is in close proximity to D6S1624 microsatellite locus.

HLA-E belongs to a non-classical HLA class Ib group of molecules which are homologous to classical HLA class Ia molecules but are characterized by a limited polymorphism and low cell surface expression (13). Transcripts of this gene have been found in a variety of different tissues (14). HLA-E may be involved in the regulation of Natural killer (NK) cell function by presenting leader peptide derived from HLA-A, B, C and G molecules to interact with NK cell receptors and affects inhibiting or activating function of NK cell-mediated lysis (15-18). Recent study has shown that different HLA-E alleles can affect different functions of natural killer cells (19). In addition, several observations raise the possibility that HLA-E might plays an important role in the regulation of cytotoxic T lymphocyte (CTL) function, as CD94/NKG2 receptors are expression on a subset of CTL cell function (20,21). Furthermore, there is evidence that HLA-E can interact with T cell receptors (TCRs). The data imply the generation of human T cells potentially recognizing through the  $\alpha\beta$ TCR-HLA-E molecules that bind to class I- and virus-derived peptides (22). The aim of this study was to investigate the association between HLA-E and genetic susceptibility to nasopharyngeal carcinogenesis by comparing the frequencies of HLA-E alleles in 104 Thai patients with NPC and 100 healthy controls.

## **Material and methods**

### **Subjects**

After having obtained the subjects' informed consent as to purpose of the study blood samples were collected by venipuncture. This study has been approved by The Ethics Committee of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. One hundred and four Thai patients with NPC who attended at King Chulalongkorn Memorial Hospital from 1994 to 2001 and 100 control samples from healthy blood donors in Thai Red Cross Society. The tumor of every patient was histologically ascertained as NPC type II or III,

according to WHO classification. These patients' ages ranged from 5 to 82 years (mean 41.2) at the time of diagnosis whereas the control subjects ages ranged from 18 to 59 years (mean 34.7). Males outnumber females among the cases was 1.8: 1 and among the controls 1.4: 1, respectively.

### **Extraction and amplification of genomic DNA**

Molecular genetic analysis was performed on genomic DNA, obtained from peripheral blood lymphocytes using standard phenol-chloroform extraction procedure as previously described (23). Exon 2 and exon 3 were separately amplified by polymerase chain reaction (PCR) using primers HLA-E.2F [5' GAA ACG GCC TCT ACC GGG AGT AG 3']- HLA-E.2R [5' GTT CCG CAG CCT TGG GGT GAA TC 3'] and HLA-E.3F [5' CGG GAC TGA CTA AGG GGC 3']-HLA-E.3R [5' AGC CCT GTG GAC CCT CTT 3'] (24,25).

### **HLA-E typing**

Twelve SSOPs (Sequence specific oligonucleotide probes) were used for oligotyping of HLA-E alleles. Ten SSOPs were described previously (25). Two SSOPs of codon150 were designed in this study [GATGCCTCTGAGGCG and GATGCTTCTGAGGCG ]. The DNA typing of HLA-E gene was performed by dot-blot hybridization method. The SSOPs were labeled with  $\gamma$ -<sup>32</sup>P-ATP (Amersham, England) and T4 polynucleotide kinase (New England BioLab, USA). PCR products were spotted onto nylon membrane (Hybond-N; Amercham, England), immobilized by denaturing solution [1.5 M NaCl and 0.5 M NaOH] and neutralized with neutralizing solution [1.5 NaCl, 0.5 M Tris-HCl (pH 7.2) and 0.5 M EDTA (pH 8.0)]. Prehybridization of the membrane was performed in a hybridization oven (Stuart Scientific, England) for 15 minutes at 42°C, in 10 ml of hybridization solution per 100 cm<sup>2</sup> of membrane (5x standard saline citrate [SSC], 1% blocking agent, 1% N-lauroylsarcosine, and 0.02% sodium dodecyl sulfate [SDS]). Hybridization was carried out at 42°C for 1 hour with  $\gamma$ -<sup>32</sup>P-ATP

labeled-SSOPs. Posthybridization washing was done as follow: 5xSSC at 42°C for 10 minutes and twice for 10 minutes at 50°C in the same solution. Hybridization signals were detected by exposure the blots DNA to a phosphor screen and visualized on PhosphorImager using ImageQuaNT software (Molecular Dynamics, USA).

### **DNA sequencing**

Sequencing was used to screen for additional polymorphism at other locations besides the one previously characterized and used to confirm the accuracy of PCR-SSOPs results. For direct cycle sequencing, 40 µl of the PCR products were purified by the QIAquick PCR Purification Kit (QIAGEN Inc.) to obtain clean double-stranded DNA amplicates. Approximately 100 ng each of PCR products were sequenced with both directions of exon 2 and exon 3 primers as previously described (24,25). Cycle sequencing was performed on an ABI Prism 310 Genetic Analyzer using a cycle sequencing chemistry with base-specific fluorescence – labeled dideoxynucleotide termination reagents, BigDye Terminator Ready Reaction Mix (Applied Biosystems) was used for sequencing.

### **Statistical analysis**

The number of HLA-E alleles was obtained using gene counting. The association between certain alleles of HLA-E gene and NPC was estimated by the statcalc from Epi info version 6 program ([http:// www. Cdc.gov/epiinfo/EI6dnjp.htm](http://www.Cdc.gov/epiinfo/EI6dnjp.htm)) to calculate the odds ratio (OR) and 95% confidence interval (CI), Yates' corrected chi-squares and associated p values. P values of <0.05 were considered to be significant.

### **Results**

HLA-E genotypes or alleles of 104 patients with NPC and 100 healthy individuals were investigated by PCR-SSOP method. Sequence results did not reveal any new polymorphism at the other locations besides the one previously characterized. The determination of each allele depends on the presence of specific nucleotide as earlier described (26). For example, the HLA-E\*0101 allele presents with polymorphism at the codon 83 (G/C) and the codon 107(A/G) both consisting in missense substitutions. A nonsynonymous conservative change from glycine to arginine at position 83(G/C) and a synonymous change of the codon 82(C/G) define the HLA-E\*0102. The HLA-E\*0103 lineage correspond to HLA-EG [A pattern of nucleotide substitution of HLA-E gene, which is Guanine (G)] at codon 107. The HLA-E\*0103 comprised E\*01031, E\*01032 and E\*01033. A silent substitution (C/T) at codon 77 in exon 2 distinguished E\*01032 from E\*01031. The HLA-E\*01033 allele corresponds to HLA-ET [A pattern of nucleotide substitution of HLA-E gene, which is Thymine (T)] at codon 150. The HLA-E\*0104 allele is defined by a silent substitution at codon 2 (C/T) or a nonsynonymous change from arginine to glycine at amino acid position 157 (A/G). In this study, three alleles of HLA-E could be detected on the basis of these polymorphism which composed of HLA-E\*0101, 01031 and 01032. When analyzing the association between genotypes or alleles of HLA-E and NPC, the HLA-E\*0103 lineage (E\*01031 and E\*01032) were combined together because both of them correspond to HLA-EG at codon 107. The codon 107(A/G) of HLA-E is a mutation altering the amino acid arginine to glycine. There was a significant increase in the frequency of the HLA-E\*0103, 0103 genotype in the patients compared to the normal controls ( $p = 0.0141$ , OR = 2.11, 95% CI = 1.15-3.88). None of the other genotypes showed any significant association (Table 1). A significant increase in the frequency of the HLA-E\*0103 allele was found in the patients compared to normal controls ( $p = 0.0076$ , OR = 1.78, 95% CI = 1.16-2.74). The HLA-E allelic frequencies in the patients and normal controls are shown in Table 2.

## Discussion

A previous study has shown that the D6S1624 microsatellite is strongly associated with NPC (12). HLA-E is in close proximity to this microsatellite marker and is candidate gene that related with function of NK and CTL cells, which are important immune cells against tumor. In this study, the results showed that the NPC susceptibility is associated with certain HLA-E genotypes and alleles. HLA-E\*0103, 0103 genotype and HLA-E\*0103 allele are associated with NPC. These might suggest a possible important role for HLA-E in NPC development.

Since NPC is a complex disease, HLA-E gene might be one of several causes for NPC development. In addition, there may be some other genes in this region that play a role in the susceptibility to NPC that are in linkage disequilibrium with HLA-E. If HLA-E107G is a true disease allele, which is likely one of several causes for NPC development. Various explanations that can link HLA-E to NPC development were discussed. Firstly, HLA-E plays an important role in NK cell function. HLA-E has been found to present class I leader peptides and to be recognized by NK cells (27,28). According to HLA-E\*0103 allele is defined by a missense mutation at codon 107, which change from arginine to glycine. One experiment supporting function of HLA-E\*0103 (glycine) to present the leader peptide of certain HLA-A, -B, -C and -G alleles to NK cell receptors and affect different NK cell function. HLA-E presents the leader peptide from A2, which is common type in most population and there are reports that HLA-A2 was associated with NPC (29,30). So, it is possible that HLA-E\*0101 (arginine) presents the leader peptide from HLA-A2 leading to no inhibition in NK cell-mediated lysis. Whereas HLA-E\*0103 allele with the leader peptide from HLA-A2 will inhibit NK cell-mediated lysis (19). It would be interesting to further characterize HLA-A together with HLA-E allele in NPC patients. In addition, One study showed the relation between NPC and NK cell that NK cell activity of NPC patients lower significantly than controls (31). This might be the effect of HLA-E107G allele to inhibit NK cell-mediated lysis. Secondly, according to the crystal structure of HLA-E

(32), the amino acid at position 107 is found in a loop between the  $\beta$ -pleats at the base of the antigen binding cleft in the  $\alpha$ -2 domain. This position is not placed in the peptide-binding region but rather in the T cell receptor-contacting region. Recent studies demonstrated that HLA-E complexed with class I signal sequence-derived peptides is not only a ligand for NK cell inhibitory receptors, but can also interact with TCR and trigger CTL (33). Yet, no direct proof for functional implication of CTL response in the interaction between TCR and each HLA-E allele bind to EBV peptides. Several observations raise the possibility that HLA-E might plays an important role in the regulation of CTL function, as CD94/NKG2 receptors are also expressed on T cells in particular on those with an activated or memory phenotype (21,34). The functional role of HLA-E-NK cell receptor recognition on CTLs remains unclear. However, future studies would be interesting to test the functional properties of the HLA-E alleles in NK cell or CTL for NPC patients.

### Acknowledgments

The study was supported by Ministry of University Affairs (MUA)-CU Thesis Grant, the Molecular Biology Project, Faculty of Medicine, Chulalongkorn University and Thailand Research Fund. The authors are deeply indebted to the staff of the Department of Otolaryngology and the Radiotherapy Section, Department of Radiology, Faculty of Medicine, Chulalongkorn University. And National Blood Center for the recruitment of patients and collection of materials.

## References

1. Chan SH, Chew CT, Prasad U et al. HLA and nasopharyngeal carcinoma in Malays. *Br J Cancer* 1985; **51**: 389-392.
2. Ren EC and Chan SH. Human leucocyte antigens and nasopharyngeal carcinoma. *Clin Sci (Colch)* 1996; **91**: 256-258.
3. Liebowitz D. Nasopharyngeal carcinoma: The Epstein-Barr virus association. *Seminars in Oncology* 1994; **21**: 376-381.
4. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. Preserved foods and nasopharyngeal carcinoma: a case-control study among Singapore Chinese. *Int J Cancer* 1994; **59**: 585-90.
5. Zheng YM, Tuppin P, Hubert A et al. Environmental and dietary risk factors for nasopharyngeal carcinoma : a case control study in Zanhwu County, Guangxi, China. *Br J Cancer* 1994; **69**: 508-14.
6. Armstrong RW, Imrey PB, Lye MS, Armstrong MJ, Yu MC, Sani S. Nasopharyngeal carcinoma in Malaysian Chinese: salted fish and other dietary exposures. *Int J Cancer* 1998; **77**: 228-35.
7. Clifford P. A review on the epidemiology of nasopharyngeal carcinoma. *Int J Cancer* 1970; **5**: 287-309.
8. Simons MJ, Wee GB, Goñ EH, Chan SH, Shanmugaramnam K, Day NE. et al. Immunogenetic aspects of nasopharyngeal carcinoma. IV. Increased risk in Chinese of

- nasopharyngeal carcinoma associated with a Chinese-related HLA profile (A2, Singapore 2). J Natl Cancer Inst 1976: 57: 977-80.
9. Chan SH, Day NE, Kunaratnam N, Chia KB, Simons MJ. HLA and nasopharyngeal carcinoma in Chinese--a further study. Int J Cancer 1983: 32: 171-6.
  10. Pimtanothai N, Charoenwongse P, Mutirangura A, Hurley CK. Distribution of HLA-B alleles in nasopharyngeal carcinoma patients and normal controls in Thailand. Tissue Antigens 2002: 59: 223-5.
  11. Lu SJ, Day NE, Degos L et al. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature 1990: 346 : 470-471.
  12. Ooi EE, Ren EC and Chan SH. Association between microsatellites within the human MHC and nasopharyngeal carcinoma. Int J Cancer 1997: 74 : 229-232.
  13. Shawar SM, Vyas JM, Rodgers JR, Rich RR. Antigen presentation by major histocompatibility complex class I-B molecules. Annu Rev Immunol 1994: 12: 839-80.
  14. Wei XH, Orr HT. Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue. Hum Immunol 1990: 29: 131-42.
  15. Wei WI, Sham JS. Cancer of the Nasopharynx. In: Myers EN, Suen JY, ed. *Cancer of the Head and Neck*. Philadelphia: W.B. Saunders, 1996: 277-293.
  16. O'Callaghan CA. Molecular basis of human natural killer cell recognition of HLA-E (human leucocyte antigen-E) and its relevance to clearance of pathogen-infected and tumor cells. Clin Sci 2000: 99: 9-17.
  17. Houchins JP, Lanier LL, Niemi EC, Phillips JH, Ryan JC. Natural killer cell cytolytic activity is inhibited by NKG2-A and activated by NKG2-C. J Immunol 1997: 158: 3603-9.
  18. Lanier LL. Activating and inhibitory NK cell receptors. Adv Exp Med Biol 1998: 452: 13-8.

19. Maier S, Grzeschik M, Weiss EH, Ulbrecht M. Implications of HLA-E allele expression and different HLA-E ligand diversity for the regulation of NK cells. *Hum Immunol* 2000; **61**: 1059-65.
20. Mingari MC, Moretta A, Moretta L. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. *Immunol Today* 1998; **19**: 153-7.
21. Braud VM, Allan DS, McMichael AJ. Functions of nonclassical MHC and non-MHC-encoded class I molecules. *Curr Opin Immunol* 1999; **11**: 100-8.
22. Garcia P, Llano M, de Heredia AB, Willberg CB, Caparros E, Aparicio P, et al. Human T cell receptor-mediated recognition of HLA-E. *Eur J Immunol* 2002; **32**: 936-44.
23. Maniatis T, Fritsch EF, Sambrook J. *Molecular cloning: A laboratory manual*. 2<sup>nd</sup> ed. New York: Cold Spring Harbor, 1989: 9.16-9.23.
24. Hodgkinson AD, Millward BA and Demaine AG. The HLA-E locus is associated with age at onset and susceptibility to type 1 diabetes mellitus. *Hum Immunol* 2000; **61**: 290-5.
25. Gomez-Casado E, Martinez-Laso J and Vargas-Alarcon G. Description of a new HLA-E (E\*01031) allele and its frequency in the Spanish population. *Hum Immunol* 1997; **54**: 69-73.
26. Steffensen R, Christiansen OB, Bennett EP, Jersild C. HLA-E polymorphism in patients with recurrent spontaneous abortion. *Tissue Antigens* 1998; **52**: 569-72.
27. Lee N, Llano M, Carretero M et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. *Proc Natl Acad Sci U S A* 1998; **95**: 5199-204.
28. Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. *J Immunol* 1998; **160**: 4951-60.
29. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. *Nature* 1998; **391**: 795-9.

30. Llano M, Lee N, Navarro F, Garcia P, Albar JP, Geraghty DE, et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. *Eur J Immunol* 1998; **28**: 2854-63.
31. Lynn TC, Wang JH, Yang CS, Tu SM. [Natural killer cell activity in patients with nasopharyngeal carcinoma]. *Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi* 1986; **19**: 177-82.
32. O'Callaghan CA, Tormo J, Willcox BE et al. Production, crystallization, and preliminary X-ray analysis of the human MHC class Ib molecule HLA-E. *Protein Sci* 1998; **7**: 1264-6.
33. Martinozzi S, Pacasova R, Boulouis HJ et al. Cutting edge: requirement of class I signal sequence-derived peptides for HLA-E recognition by a mouse cytotoxic T cell clone. *J Immunol* 1999; **162**: 5662-5.
34. McMahon CW, Raulet DH. Expression and function of NK cell receptors in CD8+ T cells. *Curr Opin Immunol* 2001; **13**: 465-70.

**Table 1 Frequency of HLA-E genotypes in patients with NPC and normal controls**

| HLA-E genotypes | % of patients (n) | % of controls (n) | P value             | OR (95% CI)         |
|-----------------|-------------------|-------------------|---------------------|---------------------|
| 0101            | 9.62 (10)         | 18 (18)           |                     |                     |
| 0101; 0102      | 0 (0)             | 0 (0)             |                     |                     |
| 0101; 0103      | 39.42 (41)        | 49 (49)           |                     |                     |
| 0101; 0104      | 0 (0)             | 0 (0)             |                     |                     |
| 0102            | 0 (0)             | 0 (0)             |                     |                     |
| 0102; 0103      | 0 (0)             | 0 (0)             |                     |                     |
| 0102; 0104      | 0 (0)             | 0 (0)             |                     |                     |
| 0103            | 50.96 (53)        | 33 (33)           | 0.0141 <sup>1</sup> | 2.11<br>(1.15-3.88) |
| 0103; 0104      | 0 (0)             | 0 (0)             |                     |                     |
| Total (n)       | 104               | 100               |                     |                     |

The number of individuals is given in parentheses.

<sup>1</sup> Chi-square probability for the comparison of HLA-E genotypes in patients and controls.

**Table 2 Frequency of HLA-E alleles in patients with NPC and normal controls**

| HLA-E alleles | % of patients (n) | % of controls (n) | P value             | OR (95% CI)         |
|---------------|-------------------|-------------------|---------------------|---------------------|
| 0101          | 29.33 (61)        | 42.5 (85)         |                     |                     |
| 0102          | 0 (0)             | 0 (0)             |                     |                     |
| 0103          | 70.77 (147)       | 57.5 (115)        | 0.0076 <sup>1</sup> | 1.78<br>(1.16-2.74) |
| 0104          | 0 (0)             | 0 (0)             |                     |                     |
| Total (n)     | 208               | 200               |                     |                     |

The number of individuals is given in parentheses.

<sup>1</sup> Chi-square probability for the comparison of HLA-E alleles in patients and controls.